Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/15—Reoviridae, e.g. calf diarrhea virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
  • A61K2039/552—Veterinary vaccine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
  • A61K2039/6025—Nucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
  • A61K2039/6031—Proteins
  • A61K2039/6056—Antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/70—Multivalent vaccine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
  • C12N2720/00011—Details
  • C12N2720/12011—Reoviridae
  • C12N2720/12311—Rotavirus, e.g. rotavirus A
  • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
  • C12N2720/00011—Details
  • C12N2720/12011—Reoviridae
  • C12N2720/12311—Rotavirus, e.g. rotavirus A
  • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
  • C12N2720/00011—Details
  • C12N2720/12011—Reoviridae
  • C12N2720/12311—Rotavirus, e.g. rotavirus A
  • C12N2720/12351—Methods of production or purification of viral material
  • C12N2720/12352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
  • C12N2720/00011—Details
  • C12N2720/12011—Reoviridae
  • C12N2720/12311—Rotavirus, e.g. rotavirus A
  • C12N2720/12371—Demonstrated in vivo effect

Definitions

• the present invention relates to immunogenic compositions comprising recombinantly constructed polypeptides useful for reducing one or more clinical signs caused by a rotavirus infection. More particular, the present invention is directed to an immunogenic composition containing (i) a fusion protein comprising in N- to C-terminal direction (A) an immunogenic fragment of a rotavirus VP8 protein and (B) an immunoglobulin Fc fragment such as, for example, an IgG Fc fragment, and (ii) an immunogenic substance, different from said fusion protein, wherein said immunogenic composition is usable in a method of reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in swine.
• Rotaviruses are double-stranded RNA viruses which comprise a genus within the family Reoviridae. Rotavirus infection is known to cause gastrointestinal disease and is considered the most common cause of gastroenteritis in infants. Rotavirus is transmitted by the faecal- oral route and infects cells that line the small intestine. Infected cells produce an enterotoxin, which induces gastroenteritis, leading to severe diarrhea and sometimes death through dehydration.
• Rotaviruses possess a genome composed of 11 segments of double-stranded RNA (dsRNA) and are currently classified into eight groups (A-H) based on antigenic properties and sequence-based classification of the inner viral capsid protein 6 (VP6), as defined by the International Commitee on Taxonomy of Viruses (ICTV) and summarized by Matthijnssens et al. (Arch Virol 157:1177-1182 (2012)), wherein this and the following publications referred to herein are incorporated by reference in their entirety.
• dsRNA double-stranded RNA
• A-H antigenic properties and sequence-based classification of the inner viral capsid protein 6 (VP6), as defined by the International Commitee on Taxonomy of Viruses (ICTV) and summarized by Matthijnssens et al. (Arch Virol 157:1177-1182 (2012)), wherein this and the following publications referred to herein are incorporated by reference in their entirety.
• the genome of rotavirus encodes six structural proteins (VP1-VP4, VP6 and VP7) and six non- structural proteins (NSP1-NSP6), wherein genome segments 1-10 each encode one rotavirus protein, and genome segment 11 encodes two proteins (NSP5 and NSP6).
• VP7 and VP4 are components of the outermost protein layer (outer capsid), and both carry neutralizing epitopes.
• VP7 is a glycoprotein (thus designated “G”) that forms the outer layer or surface of the virion. VP7 determines the G-type of the strain and the designations for G serotypes and G genotypes are identical.
• VP4 is protease sensitive (thus designated “P”) and determines the P-type of the virus.
• the numbers assigned for P serotypes and genotypes are different (Santos N. et Hoshino Y., 2005, Reviews in Medical Virology, 15, 29-56). Therefore, the P serotype is designated as P followed by assigned number, and the P genotype is designated by a P followed by assigned number in brackets (e.g., “P[7]” or “P[13]”). Strains that belong to the same genotype have higher than 89% amino acid sequence identity (Estes and Kapikian. Rotaviruses. In: Knipe, D.M.; Howley, P.M.
• Rotaviruses are in particular also a major cause of gastroenteritis in swine with antibodies against group A and C rotaviruses present in nearly 100% of pigs (Vlasova et al. Viruses. 9(3): 48 (2017)).
• Currently, only modified live or killed vaccines are available against rotavirus A.
• the inability to culture rotavirus C in the laboratory has hampered development of a vaccine against this group, which then adds to the attractiveness of a recombinant vaccine.
• a recombinant anti-rotavirus vaccine is hindered by the complexity of the rotavirus capsid, which is composed of four proteins arranged in three layers.
• the resulting symmetry mismatch between VP2 and VP6 produces five distinct VP6 trimer positions and three distinct pore types.
• VP6 readily forms ordered high molecular weight microtubules and spheroids in a salt and pH-dependent manner which may represent byproducts of viral assembly.
• VP6 layer is covered by 260 Ca2+-dependent trimers of VP7 which act as a clamp holding the VP4 spike in place.
• VP7 is the glycosylated or G-type antigen, and contains neutralizing epitopes. The majority of neutralizing antibodies recognize only trimeric VP7 and are thought to act by preventing dissociation of the VP7 trimer which in turn blocks release of the spike.
• Rotavirus spikes are present as 60 trimers of VP4 which are inserted into the VP6 layer only at pore type II.
• VP4 contains neutralizing epitopes and is the P-type antigen, cleaved by trypsin into spike base VP5* and cellular interaction head VP8*, which remains associated with VP5* following cleavage. Trypsinization primes the spike for cellular entry, during which the spike undergoes profound structural rearrangement to expose active sites for receptor binding on host cells. Ignoring the complexities of the above assembly process, stoichiometric expression of rotavirus capsid proteins with environmental conditions to promote proper assembly are difficult to achieve.
• VP7 and VP4 are the two proteins that contain neutralizing epitopes, however use of VP7 would have been complicated by its glycosylation and calcium-dependent trimerization. Use of VP4 is complicated by its trimerization, trypsinization, and range of potential conformational states.
• VP8 protein Furthermore, within the VP8 protein, it is the lectin-like domain (aa65-224) which is considered to interact with the host receptor and to be involved in the attachment of the virus to the host cell (Rodriguez et a!., PloS Pathog. 10(5):e1004157 (2014)).
• VP8-1 N-terminal truncated VP8 protein
• CTB pentameric fusion proteins
• VP8-1 N-terminally fused to CTB was considered as a viable candidate for further development, as compared to VP8-1-CTB, it showed higher binding activity to GM1 or to conformation sensitive neutralizing monoclonal antibodies specific to VP8*, and elicited higher titers of neutralizing antibodies and conferred higher protective efficacy, in a mouse model (Xue et al. Hum Vaccin Immunother. 12(11) 2959-2968 (2016)).
• the invention is based on the surprising finding that the administration of a polypeptide comprising a fragment of a rotavirus VP8 protein, namely an N-terminally extended lectin-like domain, being linked at the C-terminus with an IgG Fc fragment, to sows significantly reduced, via passive transmission of neutralizing antibodies, the diarrhea and fecal shedding in their offspring after challenge with rotavirus, even when said polypeptide was mixed, before administration, with additional immunogenic substances.
• the invention thus relates to an immunogenic composition which comprises
• the immunogenic composition of the present invention is thus in particular a composition comprising two components (i; ii), namely (i) a polypepetide comprising an immunogenic fragment of a rotavirus VP8 protein, and an immunoglobulin Fc fragment, wherein said polypeptide is hereinafter also termed “component (i) of the immunogenic composition of the present invention” or “component (i)”, respectively, and
• component (ii) of the immunogenic composition of the present invention or “component (i i)”, respectively.
• polypeptide comprising an immunogenic fragment of a rotavirus VP8 protein
• an immunoglobulin Fc fragment an immunogenic fragment of a rotavirus VP8 protein, which is described herein in the context of the present invention is also termed “the polypeptide of the present disclosure” hereinafter.
• component (i) of the immunogenic composition of the present invention is a polypeptide of the present disclosure.
• component (ii) consists of two, three or more immunogenic substances, wherein all of said immunogenic substances are different from component (i) and different from each other.
• an immunogenic composition can be simply produced, as the polypeptide of the present disclosure, when produced in cells, is released from the cells, and can then be recovered from the supernatant surrounding the cells rather than from the cells themselves. Subsequently, the recovered polypeptide can be easily mixed with the further component(s), including the at least one immunogenic substance, different from said polypeptide, to produce the immunogenic composition of the present invention.
• polypeptide of the present disclosure may be prepared as one polypeptide comprising/presenting two immunogenic fragments of different rotaviruses, thereby making it unnecessary to separately prepare two different monovalent polypeptides which then need to be combined for the same purpose.
• the immunoglobulin Fc fragment as described herein, is linked to
• said immunoglobulin Fc fragment is preferably linked to
• immunoglobulin Fc fragment as described herein, is linked to
• the immunoglobulin Fc fragment as described herein, is linked to the C- terminus of said immunogenic fragment of a rotavirus VP8 protein.
• polypeptide of the present disclosure is in particular a polypeptide comprising an immunogenic fragment of a rotavirus VP8 protein, and an immunoglobulin Fc fragment, wherein said immunoglobulin Fc fragment is linked to the C-terminus of said immunogenic fragment of a rotavirus VP8 protein.
• polypeptide used herein in particular refers to any chain of amino acid residues linked together by peptide bonds, and does not refer to a specific length of the product.
• polypeptide may refer to a long chain of amino acid residues, e.g. one that is 150 to 600 amino acid residues long or longer.
• polypeptide includes polypeptides having one or more post-translational modifications, where post-translational modifications include, e.g., glycosylation, phosphorylation, lipidation (e.g., myristoylation, etc.), acetylation, ubiquitylation, sulfation, ADP ribosylation, hydroxylation, Cys/Met oxidation, carboxylation, methylation, etc..
• post-translational modifications include, e.g., glycosylation, phosphorylation, lipidation (e.g., myristoylation, etc.), acetylation, ubiquitylation, sulfation, ADP ribosylation, hydroxylation, Cys/Met oxidation, carboxylation, methylation, etc.
• post-translational modifications include, e.g., glycosylation, phosphorylation, lipidation (e.g., myristoylation, etc.), acetylation, ubi
• immunogenic fragment is in particular understood to refer to a fragment of a protein, which at least partially retains the immunogenicity of the protein from which it is derived.
• an “immunogenic fragment of a rotavirus VP8 protein” is particularly understood to refer to a fragment of a rotavirus VP8 protein, which at least partially retains the immunogenicity of the full length VP8 protein.
• an "immunogenic substance” refers to any substance capable of eliciting a humoral and/or cellular immune response, in particular to a molecule such as a peptide or polypeptide capable of eliciting, producing, or generating an immune response in an animal.
• VP8 protein as described herein, is understood to be in particular equivalent to “VP8 domain”, “VP8*” or “VP8 fragment of VP4”, as frequently used in the context of rotavirus.
• immunoglobulin Fc fragment refers to a protein that contains the heavy-chain constant region 2 (CH2) and the heavy-chain constant region 3 (CH3) of an immunoglobulin and, more particular, that does not contain the variable regions of the heavy and light chains, and the light-chain constant region 1 (CL1) of the immunoglobulin. It may further include the hinge region, or a portion of the hinge region, of the immunoglobulin (i.e. , the hinge region at the heavy-chain constant region). Also, the immunoglobulin Fc fragment may contain a part or all of the heavy-chain constant region 1 (CH1).
• CH2 heavy-chain constant region 2
• CH3 heavy-chain constant region 3
• CL1 light-chain constant region 1
• immunoglobulin Fc fragment is equivalent to “immunoglobulin Fc domain”.
• linked to in particular refers to any means for connecting, within a polypeptide, an immunoglobulin Fc fragment to the C-terminus or N-terminus of an immunogenic fragment of a rotavirus VP protein.
• linking means examples include (1.) indirect linkage of the immunoglobulin Fc fragment to the C-terminus of an immunogenic fragment of a rotavirus VP 8 protein by an intervening moiety which is directly linked to the C- terminus of said immunogenic fragment of a rotavirus VP8 protein, and which also binds said immunoglobulin Fc fragment, and (2.) direct linkage of the immunoglobulin Fc fragment to the C-terminus of an immunogenic fragment of a rotavirus VP8 protein by covalent bonding.
• the terms "linked to” and “linked with” are used interchangeably in the context of the present invention.
• polypeptide comprising an immunogenic fragment of a rotavirus VP8 protein, and an immunoglobulin Fc fragment, wherein said immunoglobulin Fc fragment is linked to the C-terminus of said immunogenic fragment of a rotavirus VP8 protein is in particular equivalent to the wording
• polypeptide comprising, in N- to C-terminal direction, the amino acid sequence of an immunogenic fragment of a rotavirus VP8 protein, and the amino acid sequence of an immunoglobulin Fc fragment”, or to the wording
• polypeptide comprising an immunogenic fragment of a rotavirus VP8 protein, and an immunoglobulin Fc fragment linked to the C-terminus of said immunogenic fragment.
• the immunoglobulin Fc fragment is linked to the C- terminus of said immunogenic fragment of a rotavirus VP8 protein via a linker moiety.
• the linker moiety as described herein in the context of the present invention, is preferably a peptide linker.
• peptide linker refers to a peptide comprising one or more amino acid residues. More particular, the term “peptide linker” as used herein refers to a peptide capable of connecting two variable proteins and/or domains, e.g. an immunogenic fragment of a rotavirus VP8 protein and an immunoglobulin Fc fragment.
• the immunoglobulin Fc fragment is linked to the C-terminus of said immunogenic fragment of a rotavirus VP8 protein via a linker moiety, wherein
• the immunogenic fragment of a rotavirus VP8 protein is linked to the linker moiety via a peptide bond between the N-terminal amino acid residue of the linker moiety and the C-terminal amino acid residue of the immunogenic fragment of a rotavirus VP8 protein, and
• the linker moiety is linked to the immunoglobulin Fc fragment via a peptide bond between the N-terminal amino acid residue of the immunoglobulin Fc fragment and the C-terminal amino acid residue of the linker moiety.
• the immunoglobulin Fc fragment is linked to the immunogenic fragment of a rotavirus VP8 protein via a peptide bond between the N-terminal amino acid residue of the immunoglobulin Fc fragment and the C-terminal amino acid residue of the immunogenic fragment of a rotavirus VP8 protein.
• polypeptide of the present disclosure is in particular a fusion protein.
• fusion protein means a protein formed by fusing (i.e. , joining) all or part of two or more polypeptides which are not the same. Typically, fusion proteins are made using recombinant DNA techniques, by end to end joining of polynucleotides encoding the two or more polypeptides. More particular, the term “fusion protein” thus refers to a protein translated from a nucleic acid transcript generated by combining a first nucleic acid sequence that encodes a first polypeptide and at least a second nucleic acid that encodes a second polypeptide, where the fusion protein is not a naturally occurring protein. The nucleic acid construct may encode two or more polypeptides that are joined in the fusion protein.
• polypeptide of the present disclosure is a fusion protein of the formula x-y-z, wherein x consists of or comprises an immunogenic fragment of a rotavirus VP8 protein; y is a linker moiety; and z is an immunoglobulin Fc fragment.
• the formula x-y-z is in particular to be understood that the C-terminal amino acid residue of said immunogenic fragment of a rotavirus VP8 protein is linked with said linker moiety, preferably via a peptide bond with the N-terminal amino acid residue of said linker moiety, and that the N-terminal amino acid residue of said immunoglobulin Fc fragment is linked with said linker moiety, preferably via a peptide bond with the C-terminal amino acid residue of said linker moiety.
• x consists of an immunogenic fragment of a rotavirus VP8 protein”, as described herein, is in particular understood to be equivalent to “x is an immunogenic fragment of a rotavirus VP8 protein”.
• the immunogenic fragment of a rotavirus VP8 protein is preferably capable of inducing an immune response against rotavirus in a subject to whom said immunogenic fragment of a rotavirus VP8 protein is administered.
• the immunogenic fragment of a rotavirus VP8 protein is a polypeptide being 50 to 200, preferably 140 to 190 amino acid residues, in length.
• the rotavirus mentioned herein is preferably selected from the group consisting of rotavirus A and rotavirus C.
• the immunogenic fragment of a rotavirus VP8 protein is preferably selected from the group consisting of immunogenic fragment of a rotavirus A VP8 protein and immunogenic fragment of a rotavirus C VP8 protein.
• rotavirus A and rotavirus C relate(s) to rotavirus A and rotavirus C, respectively, as defined by the ICTV (summarized by Matthijnssens et al. Arch Virol 157:1177-1182 (2012)).
• the rotavirus mentioned herein is a porcine rotavirus.
• the rotavirus mentioned herein is rotavirus A.
• the immunogenic fragment of a rotavirus VP8 protein as described herein, is preferably an immunogenic fragment of a rotavirus A VP8 protein.
• the immunogenic fragment of a rotavirus VP8 protein comprises the lectin-like domain of a rotavirus VP8 protein.
• the “lectin-like domain of a rotavirus VP8 protein”, as mentioned herein, is understood to be preferably a lectin-like domain of a rotavirus A VP8 protein.
• a rotavirus VP8 protein in particular refers to residues 65-224 of a rotavirus VP8 protein or, respectively, corresponds to the amino acid sequence consisting of the amino acid residues 65-224 of a rotavirus VP8 protein, and wherein said amino acid residues 65-224 of a rotavirus VP8 protein are preferably the amino acid residues 65-224 of a rotavirus A VP8 protein.
• the “lectin-like domain of a rotavirus VP8 protein” preferably consists of the amino acid sequence of the amino acid residues 65-224 of a rotavirus VP8 protein, in particular of a rotavirus A VP8 protein.
• the immunogenic fragment of a rotavirus VP8 protein is an N-terminally extended lectin-like domain of a rotavirus VP8 protein, wherein the N-terminal extension is 1 to 20 amino acid residues, in particular 5 to 15 amino acid residues, in length.
• the immunogenic fragment of a rotavirus VP8 protein is an N-terminally extended lectin-like domain of a rotavirus VP8 protein, wherein the N-terminal extension is eight amino acid residues in length.
• the amino acid sequence of said N-terminal extension is preferably the amino acid sequence of the respective length flanking the N-terminal amino acid residue of the lectin-like domain in the amino acid sequence of the rotavirus VP8 protein.
• the immunogenic fragment of a rotavirus VP8 protein preferably consists of the amino acid sequence of the amino acid residues 60-224, the amino acid residues 59-224, the amino acid residues 58-224, the amino acid residues 57-224, the amino acid residues 56-224, the amino acid residues 55-224, the amino acid residues 54-224, the amino acid residues 53-224, the amino acid residues 52-224, the amino acid residues 51-224, the amino acid residues 50-224, or the amino residues 49-224, of a rotavirus VP8 protein, in particular of a rotavirus A protein.
• the immunogenic fragment of a rotavirus VP8 protein consists of the amino acid sequence of the amino acid residues 57-224 of a rotavirus VP8 protein, in particular of a rotavirus A protein.
• the above numbering of amino acid residues (e.g. “65-224” or “57-224”) is preferably with reference to the amino acid sequence of a wild-type rotavirus VP8 protein, in particular of a wild-type rotavirus A VP8 protein.
• Said wild-type rotavirus VP8 protein is preferably the protein set forth in SEQ I D NO: 1.
• the rotavirus mentioned herein is a rotavirus, in particular a rotavirus A, selected from the group consisting of genotype P[6] rotavirus, genotype P[7] rotavirus and genotype P[13] rotavirus.
• the immunogenic fragment of a rotavirus VP8 protein is preferably selected from the group consisting of immunogenic fragment of a genotype P[6] rotavirus VP8 protein, immunogenic fragment of a genotype P[7] rotavirus VP8 protein and immunogenic fragment of a genotype P[13] rotavirus VP8 protein, and is in particular selected from the group consisting of immunogenic fragment of a genotype P[6] rotavirus A VP8 protein, immunogenic fragment of a genotype P[7] rotavirus A VP8 protein and immunogenic fragment of a genotype P[13] rotavirus A VP8 protein.
• P VP4
• the rotavirus mentioned herein is a genotype P[7] rotavirus.
• the immunogenic fragment of a rotavirus VP8 protein is most preferably an immunogenic fragment of a genotype P[7] rotavirus VP8 protein, in particular an immunogenic fragment of a genotype P[7] rotavirus A VP8 protein.
• the rotavirus VP8 protein mentioned herein most preferably comprises or consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:1.
• the lectin-like domain of a rotavirus VP8 protein preferably comprises or consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:2.
• the immunogenic fragment of a rotavirus VP8 protein consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:3.
• the immunogenic fragment of a rotavirus VP8 protein consists of or is a consensus sequence of a portion of a rotavirus VP8 protein, in particular of a portion of a rotavirus A VP8 protein.
• the term "consensus sequence” in particular refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987)). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family.
• the term "consensus sequence” thus stands for a deduced amino acid sequence (or nucleotide sequence).
• the consensus sequence represents a plurality of similar sequences. Each position in the consensus sequence corresponds to the most frequently occurring amino acid residue (or nucleotide base) at that position which is determined by aligning three or more sequences.
• a consensus sequence of a portion of a rotavirus VP8 protein is obtainable by a method comprising the steps of:
• the immunogenic fragment of a rotavirus VP8 protein preferably consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with a sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:5.
• the rotavirus mentioned herein is rotavirus C.
• the immunogenic fragment of a rotavirus VP8 protein is preferably an immunogenic fragment of a rotavirus C VP8 protein.
• the immunogenic fragment of a rotavirus VP8 protein preferably consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:6.
• the immunogenic fragment of a rotavirus VP8 protein thus preferably consists of or is
• an immunogenic fragment of a rotavirus A VP8 protein in particular any of the herein described immunogenic fragments of a rotavirus A VP8 protein, or
• a consensus sequence of a portion of a rotavirus VP8 protein such as of a portion of a rotavirus A VP8 protein, preferably any of the immunogenic fragments of a rotavirus VP8 protein described herein in the context of a consensus sequence, or
• an immunogenic fragment of a rotavirus C VP8 protein in particular any of the herein described immunogenic fragments of a rotavirus C VP8 protein.
• the immunogenic fragment of a rotavirus VP8 protein is a polypeptide consisting of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with a sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.
• the immunoglobulin Fc fragment described herein is preferably at least 220 amino acid residues in length, and most preferably 220 to 250 amino acid residues in length.
• the herein described immunoglobulin Fc fragment is non-glycosylated.
• non-glycosylated in particular means that the immunoglobulin Fc fragment does not have oligosaccharide molecules attached thereto.
• the immunoglobulin Fc fragment comprises or consists of
• the immunoglobulin mentioned herein is selected from the group consisting of IgG, IgA, IgD, IgE and IgM.
• the immunoglobulin Fc fragment is preferably selected from the group consisting of IgG Fc fragment, IgA Fc fragment, IgD Fc fragment, IgE Fc fragment and IgM Fc fragment.
• the immunoglobulin Fc fragment described herein is an IgG Fc fragment.
• the IgG is preferably selected from the group consisting of lgG1 , lgG2, I gG3, 1 gG4, lgG5 and lgG6.
• the herein mentioned immunoglobulin Fc fragment is selected from the group consisting of IgG 1 Fc fragment, lgG2 Fc fragment, lgG3 Fc fragment, lgG4 Fc fragment, lgG5 Fc fragment and lgG6 Fc fragment.
• the immunoglobulin Fc fragment is a protein encoded by the genome of a species whose intestinal cells are susceptible to an infection by the rotavirus from which the immunogenic fragment of a rotavirus VP8 protein, as mentioned herein, is derived. If, for example, the fragment of a rotavirus VP8 protein is the fragment of a porcine rotavirus VP8 protein, then the immunoglobulin Fc fragment is preferably an immunoglobulin Fc fragment encoded by a porcine genome.
• the immunoglobulin Fc fragment is preferably an immunoglobulin Fc fragment encoded by a chicken genome.
• the immunoglobulin Fc fragment preferably is a swine IgG Fc fragment.
• the immunoglobulin Fc fragment comprises or consists of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:8.
• the linker moiety, or peptide linker, respectively, mentioned herein is preferably an amino acid sequence being 1 to 50 amino acid residues in length, in particular being 3 to 20 amino acid residues in length.
• the linker moiety may be a peptide linker being 3, 8 or 10 amino acid residues in length.
• the peptide linker described in the context of the present invention preferably has a length, or consists, respectively, of 1-5 amino acid residues, more preferably 2-4 amino acid residues and most preferably three amino acid residues.
• the linker moiety comprises or consists of an amino acid sequence having at least 66%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NQ:10 and SEQ ID NO:11.
• SEQ ID NO:9 refers to the amino acid sequence (in single letter code for amino acid residues): GGS, which in conventional three-letter code is Gly-Gly-Ser.
• SEQ ID NO:9 in the context of the present invention represents the amino acid sequence Gly-Gly-Ser or, respectively, “Gly Gly Ser” as set out, for the sequence of SEQ ID NO:9, in the sequence listing below.
• the polypeptide of the present disclosure has an N-terminal methionine residue flanking the N-terminal amino acid residue of the immunogenic fragment of a rotavirus VP8 protein.
• the polypeptide of the present disclosure comprises a further immunogenic fragment of a rotavirus VP8 protein linked to the C-terminus of said immunoglobulin Fc fragment.
• Said further immunogenic fragment of a rotavirus VP8 protein preferably consists of or is
• an immunogenic fragment of a rotavirus A VP8 protein in particular any of the herein described immunogenic fragments of a rotavirus A VP8 protein, or
• a consensus sequence of a portion of a rotavirus VP8 protein such as of a portion of a rotavirus A VP8 protein, preferably any of the immunogenic fragments of a rotavirus VP8 protein described herein in the context of a consensus sequence, or
• an immunogenic fragment of a rotavirus C VP8 protein in particular any of the herein described immunogenic fragments of a rotavirus C VP8 protein.
• said further immunogenic fragment of a rotavirus VP8 protein preferably comprises or consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 2 to 6.
• said further immunogenic fragment of a rotavirus VP8 protein is different from the immunogenic fragment of a rotavirus VP8 protein of which the C-terminus is linked to said immunoglobulin Fc fragment.
• Said further immunogenic fragment of a rotavirus VP8 protein is preferably linked to the C- terminus of said immunoglobulin Fc fragment via a linker moiety, in particular via any of the linker moieties described herein.
• said further immunogenic fragment of a rotavirus VP8 protein is linked to the linker moiety via a peptide bond between the N-terminal amino acid residue of said further immunogenic fragment of a rotavirus VP8 protein and the C-terminal amino acid residue of the linker moiety.
• said further immunogenic fragment of a rotavirus VP8 protein is linked to the C-terminus of said immunoglobulin Fc fragment via a peptide bond between the N-terminal amino acid residue of said further immunogenic fragment of a rotavirus VP8 protein and the C-terminal amino acid residue of said immunoglobulin Fc fragment.
• the polypeptide of the present disclosure is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.
• the polypeptide of the present disclosure is a protein comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.
• the wording “consisting of an amino acid sequence” or “consists of an amino acid sequence”, respectively, as described herein, is also directed, unless expressly mentioned otherwise, to the amino acid sequence having one or more modifications effected by the cell in which the protein or protein domain is expressed, in particular modifications of amino acid residues effected in the protein biosynthesis and/or protein processing, preferably selected from the group consisting of glycosylations, phosphorylations, and acetylations.
• At least 95% as mentioned in the context of the present invention, it is understood that said term preferably relates to “at least 96%”, more preferably to “at least 97%”, still more preferably to “at least 98%” or in particular to “at least 99%”.
• At least 99% as mentioned in the context of the present invention, it is understood that said term preferably relates to “at least 99.2%”, more preferably to “at least 99.4%”, still more preferably to “at least 99.6%” or in particular to “at least 99.8%”.
• sequence identity refers to 99.1 %, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity.
• Percent sequence identity has an art recognized meaning and there are a number of methods to measure identity between two polypeptide or polynucleotide sequences. See, e.g., Lesk, Ed., Computational Molecular Biology, Oxford University Press, New York, (1988); Smith, Ed., Biocomputing: Informatics And Genome Projects, Academic Press, New York, (1993); Griffin & Griffin, Eds., Computer Analysis Of Sequence Data, Part I, Humana Press, New Jersey, (1994); von Heinje, Sequence Analysis In Molecular Biology, Academic Press, (1987); and Gribskov & Devereux, Eds., Sequence Analysis Primer, M Stockton Press, New York, (1991).
• Methods for aligning polynucleotides or polypeptides are codified in computer programs, including the GCG program package (Devereux et al., Nuc. Acids Res. 12:387 (1984)), BLASTP, BLASTN, FASTA (Atschul et al., J. Molec. Biol. 215:403 (1990)), and Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711) which uses the local homology algorithm of Smith and Waterman (Adv. App. Math., 2:482-489 (1981)).
• sequence identity with the sequence of SEQ ID NO:X is equivalent to the term “sequence identity with the sequence of SEQ ID NO:X over the length of SEQ ID NO:X” or to the term “sequence identity with the sequence of SEQ ID NO:X over the whole length of SEQ ID NO:X”, respectively.
• X is any integer selected from 1 to 25 so that “SEQ ID NO:X” represents any of the SEQ ID NOs mentioned herein.
• the wording “group consisting of SEQ ID NO:[...], ... and SEQ ID NO:[...]”, as used herein, is interchangeable to “group consisting of: the sequence of SEQ ID NO:[...], ...and the sequence of SEQ ID NO:tinct”. “[...]” in this context is a placeholder for the number of the sequence.
• the wording “group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6” is interchangeable to “group consisting of: the sequence of SEQ ID NO:3, the sequence of SEQ ID NO:4, the sequence of SEQ ID NO:5 and the sequence of SEQ ID NO:6”.
• the polypeptide of the present disclosure consists of: an immunogenic fragment of a rotavirus VP8 protein, in particular any of the herein described immunogenic fragments of a rotavirus VP8 protein, an N-terminal methionine residue flanking the N-terminal amino acid residue of said immunogenic fragment of a rotavirus VP8 protein, and an immunoglobulin Fc fragment, in particular any of the herein described immunoglobulin Fc fragments, wherein said immunoglobulin Fc fragment is linked to the C-terminus of said immunogenic fragment of a rotavirus VP8 protein, in particular via a linker moiety, wherein said linker moiety is preferably any of the herein described linker moieties, and optionally a further immunogenic fragment of a rotavirus VP8 protein linked to the C-terminus of said immunoglobulin Fc fragment, in particular via a linker moiety, wherein said further immunogenic fragment of a rotavirus VP8 protein
• polypeptide of the present disclosure forms a dimer with a further polypeptide of the present disclosure.
• polypeptide of the present disclosure forms a homodimer with a further identical polypeptide.
• polypeptide of the present disclosure further encompasses any dimer composed of two polypeptides of the present disclosure, and in particular encompasses any homodimer composed of two identical polypeptides of the present disclosure.
• the present disclosure provides a multimer comprising or composed of a plurality of the polypeptide of the present disclosure, and wherein said multimer is also termed “the multimer of the present disclosure” hereinafter.
• the multimer of the present disclosure is a homodimer formed by one polypeptide of the present disclosure with a further identical polypeptide of the present disclosure.
• multimer of the present disclosure further encompasses any mixture of different multimers of the present disclosure, e.g. a mixture of
• component (i) of the immunogenic composition of the present invention is present in a monomer consisting of one polypeptide of the present disclosure, and/or a homodimer consisting of two identical polypeptides of the present disclosure, and/or optionally a homotrimer consisting of three identical polypeptides of the present disclosure, wherein preferably
• each of said three identical polypeptides of the present disclosure comprises or consists of the same amino acid sequence as said one polypeptide of the present disclosure.
• the present invention also encompasses an immunogenic composition which comprises
• polypeptide is included in a multimer comprising or composed of a plurality of said polypeptide, and
• the herein described at least one immunogenic substance, different from said polypeptide preferably consists of two or more immunogenic substances, wherein all of said immunogenic substances are different from said polypeptide and different from each other.
• component (ii) of the immunogenic composition of the present invention preferably consists of two or more immunogenic substances, wherein each of said immunogenic substances is different from component (i) of the immunogenic composition of the present invention, and wherein all of said immunogenic substances are different from each other.
• the at least one immunogenic substance, different from said polypeptide is at least one immunogenic substance which comprises or consists of a reovirus antigen, different from said immunogenic fragment.
• component (ii) is preferably at least one immunogenic substance comprising or consisting of a reovirus antigen, different from said immunogenic fragment of component (i).
• virus antigen in particular refers to a peptide or protein, or a part thereof, comprising an epitope that is recognized by an antibody specific for a virus belonging to the family Reoviridae.
• the at least one immunogenic substance, different from said polypeptide consists of two or more immunogenic substances, wherein each of said substances comprises or consists of a reovirus antigen, and wherein all of said antigens are different from said immunogenic fragment and different from each other.
• component (ii) preferably consists of two or more immunogenic substances, wherein each of said substances comprises or consists of a reovirus antigen, and wherein all of said antigens are different from said immunogenic fragment of component (i) and are different from each other.
• the at least one immunogenic substance, different from said polypeptide is at least one protein which comprises or consists of a reovirus antigen, different from said immunogenic fragment.
• component (ii) is preferably at least one protein comprising or consisting of a reovirus antigen, different from said immunogenic fragment of component (i).
• the at least one immunogenic substance, different from said polypeptide consists of two or more proteins, wherein each of said proteins comprises or consists of a reovirus antigen, and wherein all of said reovirus antigens are different from said immunogenic fragment and different from each other.
• component (ii) preferably consists of two or more proteins, wherein each of said proteins comprises or consists of a reovirus antigen, and wherein all of said antigens are different from said immunogenic fragment of component (i) and are different from each other.
• the at least one immunogenic substance, different from said polypeptide is at least one immunogenic substance which comprises a rotavirus antigen, different from said immunogenic fragment.
• component (ii) is preferably at least one immunogenic substance comprising a rotavirus antigen, different from said immunogenic fragment of component (i).
• rotavirus antigen refers to a peptide or protein, or a part thereof, comprising an epitope that is recognized by an antibody specific for a virus belonging to the genus Rotavirus.
• the at least one immunogenic substance, different from said polypeptide consists of two or more immunogenic substances, wherein each of said substances comprises or consists of a rotavirus antigen, and wherein all of said antigens are dfferent from said immunogenic fragment and different from each other.
• component (ii) preferably consists of two or more immunogenic substances, wherein each of said substances comprises or consists of a rotavirus antigen, and wherein all of said antigens are different from said immunogenic fragment of component (i) and are different from each other.
• the at least one immunogenic substance, different from said polypeptide is at least one protein which comprises or consists of a rotavirus antigen, different from said immunogenic fragment.
• component (ii) is preferably at least one protein comprising or consisting of a rotavirus antigen, different from said immunogenic fragment of component (i).
• the at least one immunogenic substance, different from said polypeptide consists of two or more proteins, wherein each of said proteins comprises or consists of a rotavirus antigen, and wherein all of said rotavirus antigens are different from said immunogenic fragment and different from each other.
• component (ii) preferably consists of two or more proteins, wherein each of said proteins comprises or consists of a rotavirus antigen, and wherein all of said antigens are different from said immunogenic fragment of component (i) and are different from each other.
• the immunogenic composition of the present invention is preferably an immunogenic composition, where in
• said polypeptide is a first polypeptide
• the at least one immunogenic substance, different from said polypeptide is at least one additional polypeptide, different from said first polypeptide.
• said at least one immunogenic substance comprises or is o a second polypeptide which comprises or consists of a reovirus antigen, different from said immunogenic fragment, and optionally comprises a third polypeptide, different from both said first and second polypeptide, and optionally comprises a fourth polypeptide, different from all of said first to third polypeptides.
• said third polypeptide comprises a reovirus antigen, different from both said immunogenic fragment and reovirus antigen of the second polypeptide.
• Said fourth polypeptide preferably comprises a reovirus antigen, different from all of said immunogenic fragment, reovirus antigen of the second polypeptide and reovirus antigen of the third polypeptide.
• component (i) of the immunogenic composition of the present invention is a first polypeptide and component (ii) of the immunogenic composition of the present invention is at least one additional polypeptide, different from said first polypeptide, and wherein preferably component (ii) comprises or is a second polypeptide which comprises a rotavirus antigen, different from said immunogenic fragment of component (i), and preferably comprises a third polypeptide, different from both said first and second polypeptide, and optionally comprises a fourth polypeptide, different from all of said first to third polypeptides.
• said third polypeptide comprises a rotavirus antigen, different from both said immunogenic fragment of component (i) and rotavirus antigen of the second polypeptide.
• said second polypeptide is any of the polypeptides of the present disclosure, as described herein, provided that said second polypeptide is different from said first polypeptide, and preferably said third polypeptide is any of the polypeptides of the present disclosure, as described herein, provided that said third polypeptide is different from both said first and second polypeptide, and optionally said fourth polypeptide is any of the polypeptides of the present disclosure, as described herein, provided that said fourth polypeptide is different from all of said first to third polypeptides.
• the immunogenic composition of the present invention is preferably an immunogenic composition, where in
• said polypeptide is a first polypeptide comprising
• the at least one immunogenic substance, different from said polypeptide comprises or consists of
• a fourth polypeptide comprising a fourth immunogenic fragment of a rotavirus VP8 protein, wherein said fourth immunogenic fragment is different from all of said first to third immunogenic fragments.
• each of said second to fourth immunogenic fragments is individually selected from the group consisting of
• an immunogenic fragment of a rotavirus A VP8 protein in particular any of the herein described immunogenic fragments of a rotavirus A VP8 protein
• a consensus sequence of a portion of a rotavirus VP8 protein such as of a portion of a rotavirus A VP8 protein, preferably any of the immunogenic fragments of a rotavirus VP8 protein described herein in the context of a consensus sequence, and
• an immunogenic fragment of a rotavirus C VP8 protein in particular any of the herein described immunogenic fragments of a rotavirus C VP8 protein, in particular provided that all of said second to fourth immunogenic fragments are different from said first immunogenic fragment and different from each other.
• said first immunogenic fragment is selected from the group consisting of X7, X13, X6 and XC
• said second immunogenic fragment is selected from the group consisting X7, X13, X6 and XC
• said third immunogenic fragment is selected from the group consisting of X7, X13, X6 and XC
• said fourth immunogenic fragments is selected from the group consisting of X7, X13, X6 and XC;
• X7 represents an immunogenic fragment of a genotype P[7] rotavirus VP8 protein
• X13 represents an immunogenic fragment of a genotype P[13] rotavirus VP8 protein
• X6 represents an immunogenic fragment of a genotype P[6] rotavirus VP8 protein
• XC represents an immunogenic fragment of a rotavirus C VP8 protein, in particular provided that all of said second to fourth immunogenic fragments are different from said first immunogenic fragment and different from each other.
• X7 means an immunogenic fragment of a genotype P[7] rotavirus VP8 protein
• X13 means an immunogenic fragment of a genotype P[13] rotavirus VP8 protein
• X6 means an immunogenic fragment of a genotype P[6] rotavirus VP8 protein
• XC means an immunogenic fragment of a rotavirus C VP8 protein.
• X7 preferably consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:3.
• X13 preferably consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:5.
• X6 as referred to herein, preferably consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:4.
• XC as referred to herein, preferably consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:6.
• the at least one immunogenic substance comprises or consists of a second polypeptide comprising a second immunogenic fragment of a rotavirus VP8 protein, and each of said first and second immunogenic fragment is individually selected from the group consisting of X7, X13, X6 and XC, provided that when said first immunogenic fragment is X7, then said second immunogenic fragment is selected from the group consisting of X13, X6 and XC, provided that when said first immunogenic fragment is X6, then said second immunogenic fragment is selected from the group consisting of X7, X13 and XC, provided that when said first immunogenic fragment is X13, then said second immunogenic fragment is selected from the group consisting of X7, X6 and XC, and provided that when said first immunogenic fragment is XC, then said second immunogenic fragment is selected from the group consisting of X7, X13 and X6.
• the at least one immunogenic substance comprises or consists of a second polypeptide comprising a second immunogenic fragment of a rotavirus VP8 protein, and a third polypeptide comprising a third immunogenic fragment of a rotavirus VP8 protein, and each of said first to third immunogenic fragments is individually selected from the group consisting of X7, X13, X6 and XC, provided that when said first immunogenic fragment is X7, then said second immunogenic fragment is X13 and said third immunogenic fragment is selected from the group consisting of X6 and XC, provided that when said first immunogenic fragment is X6, then said second immunogenic fragment is X7 and said third immunogenic fragment is selected from the group consisting of X13 and XC, provided that when said first immunogenic fragment is X13, then said second immunogenic fragment is X7 and said third immunogenic fragment is selected from the group consisting of X6 and XC, and provided that when said first immunogenic fragment is X13, then said second immunogenic
• the at least one immunogenic substance comprises or consists of a second polypeptide comprising a second immunogenic fragment of a rotavirus VP8 protein, and a third polypeptide comprising a third immunogenic fragment of a rotavirus VP8 protein, and a fourth polypeptide comprising a fourth immunogenic fragment of a rotavirus VP8 protein, wherein each of said first to fourth immunogenic fragments is individually selected from the group consisting of X7, X6, X13 and XC, provided that when said first immunogenic fragment is X7, then said second immunogenic fragment is X13, said third immunogenic fragment is X6 and said fourth immunogenic fragment is XC, provided that when said first immunogenic fragment is X6, then said second immunogenic fragment is X7, said third immunogenic fragment is X13 and said fourth immunogenic fragment is XC, provided that when said first immunogenic fragment is X13, then said second immunogenic fragment is X7, said third immunogenic fragment is X13 and said fourth immunogenic fragment
• said herein mentioned first immunogenic fragment is an immunogenic fragment of a genotype P[7] rotavirus VP8 protein (X7)
• said herein mentioned second immunogenic fragment is an immunogenic fragment of a genotype P[13] rotavirus VP8 protein (X13)
• said herein mentioned third immunogenic fragment is an immunogenic fragment of a genotype P[6] rotavirus VP8 protein (X6)
• said herein mentioned fourth immunogenic fragment is an immunogenic fragment of a rotavirus C VP8 protein (XC).
• said first immunogenic fragment is an immunogenic fragment of a genotype P[7] rotavirus VP8 protein (X7)
• said second immunogenic fragment is an immunogenic fragment of a genotype P[ 13] rotavirus VP8 protein (X13)
• said third immunogenic fragment is an immunogenic fragment of a genotype P[6] rotavirus VP8 protein (X6)
• said fourth immunogenic fragment is an immunogenic fragment of a rotavirus C VP8 protein (XC).
• said first immunogenic fragment consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:3
• said second immunogenic fragment consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:5
• said third immunogenic fragment consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:4
• said fourth immunogenic fragment consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:6.
• said first polypeptide is selected from the group consisting of R7, R13, R6 and RC
• said second polypeptide is selected from the group consisting R7, R13, R6 and RC
• said third polypeptide is selected from the group consisting of R7, R13, R6 and RC
• said fourth polypeptides is selected from the group consisting of R7, R13, R6 and RC
• R7 is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:12,
• R13 is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:14,
• R6 is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:13, and
• RC is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:15, in particular provided that all of said second to fourth polypeptides are different from said first polypeptide and different from each other.
• the at least one immunogenic substance, different from said first polypeptide comprises or consists of a second polypeptide of a rotavirus VP8 protein, and each of said first and second polypeptide is individually selected from the group consisting of R7, R13, R6 and RC, provided that when said first polypeptide is R7, then said second polypeptide is selected from the group consisting of R13, R6 and RC, provided that when said first polypeptide is R6, then said second polypeptide is selected from the group consisting of R7, R13 and RC, provided that when said first polypeptide is R13, then said second polypeptide is selected from the group consisting of R7, R6 and RC, and provided that when said first polypeptide is RC, then said second polypeptide is selected from the group consisting of R7, R13 and R6.
• the at least one immunogenic substance, different from said first polypeptide comprises or consists of a second polypeptide, and a third polypeptide
• each of said first to third polypeptides is individually selected from the group consisting of R7, R13, R6 and RC, provided that when said first polypeptide is R7, then said second polypeptide is R13 and said third polypeptide is selected from the group consisting of R6 and RC, provided that when said first polypeptide is R6, then said second polypeptide is R7 and said third polypeptide is selected from the group consisting of R13 and RC, provided that when said first polypeptide is R13, then said second polypeptide is R7 and said third polypeptide is selected from the group consisting of R6 and RC, and provided that when said first polypeptide is RC, then said second polypeptide is R7 and said third polypeptide is selected from the group consisting of R13 and R6.
• the at least one immunogenic substance, different from said polypeptide comprises or consists of a second polypeptide, and a third polypeptide, and a fourth polypeptide, wherein each of said first to fourth polypeptides is individually selected from the group consisting of R7, R6, R13 and RC, provided that when said first polypeptide is R7, then said second polypeptide is R13, said third polypeptide is R6 and said fourth polypeptide is RC, provided that when said first polypeptide is R6, then said second polypeptide is R7, said third polypeptide is R13 and said fourth polypeptide is RC, provided that when said first polypeptide is R13, then said second polypeptide is R7, said third polypeptide is R6 and said fourth polypeptide is RC, and provided that when said first polypeptide is RC, then said second polypeptide is R7, said third polypeptide is R13 and said fourth polypeptide is R6.
• said herein mentioned first polypeptide is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with the sequence of SEQ ID NO:12
• said herein mentioned second polypeptide is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ I D NO: 14, SEQ I D NO: 13 and SEQ I D NO: 15,
• said herein mentioned third polypeptide is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:13 and SEQ ID NO:15, and optionally
• an immunogenic composition of the present invention which comprises
• a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with the sequence of SEQ ID NO:12, and
• a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:13 and SEQ ID NO:15.
• an immunogenic composition of the present invention which comprises
• a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 12, and
• a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 14, and a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 13, and optionally a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 15.
• the immunogenic composition of the present invention preferably comprises each of component (i) and of the substance(s) of component (ii) in a concentration of at least 100 nM, preferably of at least 250 nM, more preferably of at least 500 nM, and most preferably of at least 1 pM.
• the immunogenic composition of the present invention contains each of component (i) and of the substance(s) of component (ii) in a concentration of 100 nM to 50 pM, preferably of 250 nM to 25 pM, and most preferably of 1-10 pM.
• a dose of the immunogenic composition of the present invention to be administered to a subject preferably has the volume of 1 mL or 2 mL.
• one dose or two doses of the immunogenic composition are administered to a subject.
• the immunogenic composition of the present invention is, preferably, administered systemically or topically. Suitable routes of administration conventionally used are parenteral or oral administration, such as intramuscular, intradermal, intravenous, intraperitoneal, subcutaneous, intranasal, as well as inhalation. However, depending on the nature and mode of action of a compound, the immunogenic composition may be administered by other routes as well. Most preferred is that the immunogenic composition is administered intramuscularly.
• the immunogenic composition of the present invention preferably further comprises a pharmaceutical- or veterinary-acceptable carrier or excipient.
• pharmaceutical- or veterinary-acceptable carrier includes any and all solvents, dispersion media, coatings, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like.
• stabilizing agents for use in the present invention include stabilizers for lyophilization or freeze-drying.
• the immunogenic composition of the present invention contains an adjuvant.
• Adjuvant as used herein, can include aluminum hydroxide and aluminum phosphate, saponins e.g., Quil A, QS-21 (Cambridge Biotech Inc., Cambridge MA), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, AL), water-in-oil emulsion, oil-in-water emulsion, water-in- oil-in-water emulsion.
• the emulsion can be based in particular on light liquid paraffin oil (European Pharmacopeia type); isoprenoid oil such as squalane or squalene; oil resulting from the oligomerization of alkenes, in particular of isobutene or decene; esters of acids or of alcohols containing a linear alkyl group, more particularly plant oils, ethyl oleate, propylene glycol di-(caprylate/caprate), glyceryl tri-(caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, in particular isostearic acid esters.
• light liquid paraffin oil European Pharmacopeia type
• isoprenoid oil such as squalane or squalene
• oil resulting from the oligomerization of alkenes in particular of isobutene or decene
• the oil is used in combination with emulsifiers to form the emulsion.
• the emulsifiers are preferably nonionic surfactants, in particular esters of sorbitan, of mannide (e.g. anhydromannitol oleate), of glycol, of polyglycerol, of propylene glycol and of oleic, isostearic, ricinoleic or hydroxy stearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Pluronic products, especially L121.
• mannide e.g. anhydromannitol oleate
• glycol of polyglycerol
• propylene glycol and of oleic isostearic, ricinoleic or hydroxy stearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Plur
• An exemplary adjuvant is the SPT emulsion described on page 147 of "Vaccine Design, The Subunit and Adjuvant Approach” edited by M. Powell and M. Newman, Plenum Press, 1995, or the emulsion MF59 described on page 183 of this same book.
• an adjuvant is a compound chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative.
• Advantageous adjuvant compounds are the polymers of acrylic or methacrylic acid which are cross-linked, especially with polyalkenyl ethers of sugars or polyalcohols. These compounds are known by the term carbomer (Phameuropa Vol. 8, No. 2, June 1996). Persons skilled in the art can also refer to U.S. Patent No.
• 2,909,462 which describes such acrylic polymers cross-linked with a polyhydroxylated compound having at least 3 hydroxyl groups, preferably not more than 8, the hydrogen atoms of at least three hydroxyls being replaced by unsaturated aliphatic radicals having at least 2 carbon atoms.
• the preferred radicals are those containing from 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups.
• the unsaturated radicals may themselves contain other substituents, such as methyl.
• the products sold under the name CARBOPOL®; (BF Goodrich, Ohio, USA) are particularly appropriate. They are cross-linked with an allyl sucrose or with allyl pentaerythritol.
• Carbopol 974P, 934P and 971 P there may be mentioned Carbopol 974P, 934P and 971 P. Most preferred is the use of CARBOPOL® 971 P.
• copolymers of maleic anhydride and alkenyl derivative are the copolymers EMA (Monsanto), which are copolymers of maleic anhydride and ethylene. The dissolution of these polymers in water leads to an acid solution that will be neutralized, preferably to physiological pH, in order to give the adjuvant solution into which the immunogenic, immunological or vaccine composition itself will be incorporated.
• Suitable adjuvants include, but are not limited to, the RIBI adjuvant system (Ribi Inc.), Block co-polymer (CytRx, Atlanta GA), SAF-M (Chiron, Emeryville CA), monophosphoryl lipid A, Avridine lipid-amine adjuvant, heat-labile enterotoxin from E. coli (recombinant or otherwise), cholera toxin, IMS 1314 or muramyl dipeptide, or naturally occurring or recombinant cytokines or analogs thereof or stimulants of endogenous cytokine release, among many others.
• an adjuvant can be added in an amount of about 100 pg to about 10 mg per dose, preferably in an amount of about 100 pg to about 10 mg per dose, more preferably in an amount of about 500 pg to about 5 mg per dose, even more preferably in an amount of about 750 pg to about 2.5 mg per dose, and most preferably in an amount of about 1 mg per dose.
• the adjuvant may be at a concentration of about 0.01 to 50%, preferably at a concentration of about 2% to 30%, more preferably at a concentration of about 5% to 25%, still more preferably at a concentration of about 7% to 22%, and most preferably at a concentration of 10% to 20% by volume of the final product.
• “Diluents” can include water, saline, dextrose, ethanol, glycerol, and the like.
• Isotonic agents can include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others.
• Stabilizers include albumin and alkali salts of ethylenediaminetetraacetic acid, among others.
• the invention also provides an immunogenic composition, in particular the immunogenic composition of the present invention, wherein the immunogenic composition comprises or consists of component (i), component (ii), a pharmaceutical- or veterinary-acceptable carrier or excipient,
• the adjuvant in the context of the present invention is preferably selected from the group consisting of an emulsified oil-in-water adjuvant and a carbomer.
• immunogenic composition refers to a composition that comprises at least one antigen, which elicits an immunological response in the host to which the immunogenic composition is administered.
• immunological response can be a cellular and/or antibody- mediated immune response to the immunogenic composition according to the invention.
• the host is also described as "subject”.
• any of the hosts or subjects described or mentioned herein is an animal.
• animal in particular relates to a mammal, preferably to swine, more preferably to a pig, most preferably to a piglet.
• an "immunological response” includes but is not limited to one or more of the following effects: the production or activation of antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T cells and/or gamma-delta T cells, directed specifically to an antigen or antigens included in the immunogenic composition of the present invention.
• the host will display either a protective immunological response or a therapeutic response.
• a "protective immunological response" will be demonstrated by either a reduction or lack of one or more clinical signs normally displayed by an infected host, a quicker recovery time and/or a lowered duration of infectivity or lowered pathogen titer in the tissues or body fluids or excretions of the infected host.
• the pathogen as mentioned herein, is a rotavirus A or a rotavirus C.
• the immunogenic composition is described as a "vaccine".
• an "antigen” as described herein refers to, but is not limited to, components which elicit an immunological response in a host to an immunogenic composition or vaccine of interest comprising such antigen or an immunologically active component thereof.
• the term “antigen” as used herein refers to a protein or protein domain, which, if administered to a host, can elicit an immunological response in the host.
• treatment and/or prophylaxis refers to the lessening of the incidence of the particular pathogen infection in a herd or the reduction in the severity of one or more clinical signs caused by or associated with the particular pathogen infection.
• treatment and/or prophylaxis generally involves the administration of an effective amount of the immunogenic composition of the present invention to a subject or herd of subjects in need of or that could benefit from such a treatment/prophylaxis.
• treatment refers to the administration of the effective amount of the immunogenic composition once the subject or at least some animals of the herd is/are already infected with such pathogen and wherein such animals already show some clinical signs caused by or associated with such pathogen infection.
• prophylaxis refers to the administration to a subject prior to any infection of such subject with a pathogen or at least where such animal or all of the animals in a group of animals do not show one or more clinical signs caused by or associated with the infection by such pathogen.
• an effective amount means, but is not limited to an amount of antigen, in particular of the polypeptide(s) of the present idisclosure, that elicits or is able to elicit an immune response in a subject. Such effective amount is able to lessen the incidence of the particular pathogen infection in a herd or to reduce the severity of one or more clinical signs of the particular pathogen infection.
• one or more clinical signs are lessened in incidence or severity by at least 10%, more preferably by at least 20%, still more preferably by at least 30%, even more preferably by at least 40%, still more preferably by at least 50%, even more preferably by at least 60%, still more preferably by at least 70%, even more preferably by at least 80%, still more preferably by at least 90%, and most preferably by at least 95% in comparison to subjects that are either not treated or treated with an immunogenic composition that was available prior to the present invention but subsequently infected by the particular pathogen.
• clinical signs refers to signs of infection of a subject from the particular pathogen.
• the clinical signs of infection depend on the pathogen selected. Examples for such clinical signs include but are not limited to diarrhea, vomiting, fever, abdominal pain, and dehydration.
• Reducing the incidence of or reducing the severity of one or more clinical signs caused by or being associated with the particular pathogen infection in a subject can be reached by the administration of one or more doses of the immunogenic composition of the present invention to a subject.
• reducing fecal shedding means, but is not limited to, the reduction of the number of RNA copies of a pathogenic virus, such as of a rotavirus, per mL of stool or the number of plaque forming colonies per deciliter of stool, is reduced in the stool of subjects receiving the composition of the present invention by at least 50% in comparison to subjects not receiving the composition and may become infected. More preferably, the fecal shedding level is reduced in subjects receiving the composition of the present invention by at least 90%, preferably by at least 99.9%, more preferably by at least 99.99%, and even more preferably by at least 99.999%.
• fecal shedding is used according to its plain ordinary meaning in medicine and virology and refers to the production and release of virus from a cell of a subject into the environment from an infected subject via the stool of the subject.
• the polypeptide of the present disclosure is preferably a recombinant protein, in particular a recombinant baculovirus expressed protein.
• recombinant protein in particular refers to a protein which is produced by recombinant DNA techniques, wherein generally DNA encoding the expressed protein is inserted into a suitable expression vector which is in turn used to transform or, in the case of a virus vector, to infect a host cell to produce the heterologous protein.
• recombinant protein as used herein, particularly refers to a protein molecule that is expressed from a recombinant DNA molecule.
• Recombinant DNA molecule refers to a DNA molecule that is comprised of segments of DNA joined together by means of molecular biological techniques.
• Suitable systems for production of recombinant proteins include but are not limited to insect cells (e.g., baculovirus), prokaryotic systems (e.g., Escherichia coli), fungi ⁇ e.g., Myceliophthora thermophile, Aspergillus oryzae, Ustilago maydis), yeast (e.g., Saccharomyces cerevisiae, Pichia pastoris), mammalian cells (e.g., Chinese hamster ovary, HEK293), plants (e.g., safflower), algae, avian cells, amphibian cells, fish cells, and cell-free systems (e.g., rabbit reticulocyte lysate).
• insect cells e.g., baculovirus
• prokaryotic systems e.g., Escherichia coli
• the present disclosure provides a polynucleotide comprising a sequence which encodes the polypeptide of the present disclosure, wherein said polynucleotide, which is also termed “the polynucleotide according to the present disclosure” hereinafter, is preferably an isolated polynucleotide.
• the polynucleotide according to the present disclosure comprises a nucleotide sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20 and SEQ ID NO:21.
• the present disclosure provides a vector containing a polynucleotide which encodes the polypeptide of the present disclosure.
• Vector refers to a suitable expression vector, preferably a baculovirus expression vector, which is in turn used to transfect, or in case of a baculovirus expression vector to infect, a host cell to produce the protein or polypeptide encoded by the DNA.
• baculovirus expression vector preferably a baculovirus expression vector, which is in turn used to transfect, or in case of a baculovirus expression vector to infect, a host cell to produce the protein or polypeptide encoded by the DNA.
• Vectors and methods for making and/or using vectors (or recombinants) for expression can be made or done by or analogous to the methods disclosed in: U.S. Pat. Nos.
• Preferred viral vectors include baculovirus such as BaculoGold (BD Biosciences Pharmingen, San Diego, CA), in particular provided that the production cells are insect cells.
• BaculoGold BD Biosciences Pharmingen, San Diego, CA
• the baculovirus expression system is preferred, it is understood by those of skill in the art that other expression systems, including those described above, will work for purposes of the present invention, namely the expression of recombinant protein.
• the disclosure also provides a baculovirus containing a polynucleotide comprising a sequence which encodes the polypeptide of the present disclosure.
• Said baculovirus which is also termed “the baculovirus according to the present disclosure” hereinafter, is preferably an isolated baculovirus.
• the disclosure thus also provides a plasmid, preferably an expression vector, which comprises a polynucleotide comprising a sequence which encodes the polypeptide of the present disclosure.
• Said plasmid which is also termed “the plasmid according to the present disclosure” hereinafter, is in particular an isolated plasmid.
• the disclosure also provides a cell infected by and/or containing a baculovirus which comprises a polynucleotide comprising a sequence which encodes the polypeptide of the present disclosure, or a plasmid, preferably an expression vector, which comprises a polynucleotide comprising a sequence which encodes the polypeptide of the present disclosure.
• Said cell which is also termed “the cell according to the present disclosure” hereinafter, is preferably an isolated cell.
• isolated when used in the context of an isolated cell, is a cell that, by the hand of man, exists apart from its native environment and is therefore not a product of nature.
• the invention also relates to the use of the immunogenic composition of the present invention for the preparation of a medicament, preferably of a vaccine.
• the invention also provides a method of producing the immunogenic composition of the present invention, wherein said method comprises the step of infecting a cell, preferably an insect cell, with the baculovirus according to the present invention.
• the disclosure also provides a method of producing the polypeptide of the present disclosure, wherein said method comprises the step of transfecting a cell with the plasmid according to the present disclosure.
• the polypeptide of the present disclosure is preferably expressed in high amounts sufficient for the stable self-assembly of virus-like particles, which may then be used for vaccination.
• vaccination or “vaccinating” as used herein means, but is not limited to, a process which includes the administration of an antigen, such as an antigen included in an immunogenic composition, to a subject, wherein said antigen, for instance the polypeptide of the present disclosure, when administered to said subject, elicits or is able to elicit, a protective immunological response in said subject
• the present invention also provides the immunogenic composition of the present invention for use as a medicament, preferably as a vaccine.
• the immunogenic composition of the present invention is provided for use in a method of reducing or preventing one or more clinical signs or disease caused by a rotavirus infection, wherein the rotavirus is preferably a rotavirus of the group having a genome encoding the immunogenic fragment of a rotavirus VP8 protein.
• the immunogenic composition of the present invention is in particular provided for use in a method of reducing or preventing the fecal shedding caused by a rotavirus infection, wherein the virus is preferably a rotavirus of the group having a genome encoding the immunogenic fragment of a rotavirus VP8 protein.
• the immunogenic composition of the present invention is for use in a method of reducing or preventing one or more clinical signs, mortality, fecal shedding or disease caused by an infection with rotavirus A.
• the immunogenic composition of the present invention is provided for use in a method of reducing or preventing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in a subject or for use in a method of treating or preventing an infection with rotavirus in a subject.
• a rotavirus infection as mentioned herein, in particular refers to an infection with a rotavirus A or rotavirus C.
• the immunogenic composition of the present invention is provided for use in a method for inducing an immune response against rotavirus in a subject.
• the subject is preferably a mammal, such as a swine or a bovine, or a bird, such as a chicken.
• the subject is a pig, and wherein the pig is preferably a piglet or a sow, such as a pregnant sow.
• the subject is a pregnant sow.
• said subject is most preferably a piglet.
• the immunogenic composition of the present invention is for use in a method of reducing or preventing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in a piglet, wherein the piglet is to be suckled by a sow to which the immunogenic composition has been administered.
• Said sow to which the immunogenic composition has been administered is preferably a sow to which the immunogenic composition has been administered while said sow has been pregnant, in particular with said piglet.
• the present invention relates to a method for the treatment or prevention of a rotavirus infection, the reduction, prevention or treatment of one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection, or the prevention or treatment of a disease caused by a rotavirus infection, comprising administering the immunogenic composition of the present invention to a subject.
• a method for inducing the production of antibodies specific for rotavirus in a preferably pregnant sow comprises administering the immunogenic composition of the present invention to said sow.
• the present invention provides a method of reducing or preventing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in a piglet, wherein said method comprises
• said sow is preferably a sow being pregnant, in particular with said pig.
• said two foregoing methods comprise the steps of administering the immunogenic composition of the present invention to a sow being pregnant with said piglet, allowing said sow to give birth to said piglet, and allowing said piglet to be suckled by said sow.
• a method of reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in a piglet is provided, wherein the piglet is to be suckled by a sow to which the immunogenic composition of the present invention has been administered.
• the one or more clinical signs are preferably selected from the group consisting of
• the one or more clinical signs mentioned herein are a rotavirus colonization of the intestine, in particular of the small intestine.
• the one or more clinical signs mentioned herein are enteric lesions, in particular macroscopic enteric lesions.
• the immunogenic composition of the present invention is for use in any of the above described methods, wherein said rotavirus infection is an infection with genotype P[23] rotavirus and/or genotype P[7] rotavirus, said infection with rotavirus is an infection with genotype P[23] rotavirus and/or genotype P[7] rotavirus, said immune response against rotavirus is an immune response against genotype P[23] rotavirus and/or genotype P[7] rotavirus, or said antibodies specific for rotavirus are antibodies specific for genotype P[23] rotavirus and/or genotype P[7] rotavirus, and wherein preferably said immunogenic composition of the present invention comprises any of the polypeptides of the present disclosure described herein comprising an immunogenic fragment of a genotype P[7] rotavirus VP8 protein, in particular consisting of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more
• an “infection with genotype P[23] rotavirus and/or genotype P[7] rotavirus”, as mentioned herein, is an infection with genotype P[23] rotavirus and genotype P[7] rotavirus.
• an “immune response against genotype P[23] rotavirus and/or genotype P[7] rotavirus”, as mentioned herein, is an immune response against genotype P[23] rotavirus.
• an “immune response against genotype P[23] rotavirus and/or genotype P[7] rotavirus”, as mentioned herein, is an immune response against genotype P[23] rotavirus and genotype P[7] rotavirus.
• the “antibodies specific for genotype P[23] rotavirus and/or genotype P[7] rotavirus”, as mentioned herein, are antibodies specific for genotype P[23] rotavirus.
• the “antibodies specific for genotype P[23] rotavirus and/or genotype P[7] rotavirus”, as mentioned herein, comprise or are antibodies specific for genotype P[23] and antibodies specific for genotype P[7] rotavirus.
• the immunogenic composition of the present invention is administered for inducing the production of antibodies specific for rotavirus C, in an animal, preferably in a pregnant sow.
• said immunogenic composition of the present invention comprises, respectively, any of the polypeptides of the present disclosure described herein comprising an immunogenic fragment of a rotavirus C VP8 protein, in particular consisting of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ I D NO: 15.
• the invention further provides a method of producing the immunogenic composition of the present invention, wherein said method comprises transfecting a cell with the plasmid of the present invention.
• a method of producing the immunogenic composition of the present invention comprises infecting a cell, preferably an insect cell, with the baculovirus of the present disclosure.
• the present invention relates to a method of producing the immunogenic composition of the present invention, wherein the method comprises the steps of:
• step (c) inactivating the vector by adding binary ethylenimine (BEI) to the mixture of step (b);
• step (d) neutralizing the BEI by adding sodium thiosulfate to the mixture resulting from step (c);
• step (e) concentrating the polypeptide in the mixture resulting from step (d) by removing a portion of the liquid from the mixture by a filtration step utilizing a filter with a filter membrane having a molecular weight cut off of between about 5 kDa and about 100 kDa, preferably between about 10 kDa and about 50 kDa; and wherein said method comprises the steps of:
• step (f) admixing the mixture remaining after step (e) with at least one immunogenic substance, different from said polypeptide;
• step (g) and optionally admixing the mixture remaining after step (f) with a further component selected from the group consisting of pharmaceutically acceptable carriers, adjuvants, diluents, excipients, and combinations thereof, or wherein said method comprises the steps of:
• step (f) admixing the mixture remaining after step (e) with a further component selected from the group consisting of pharmaceutically acceptable carriers, adjuvants, diluents, excipients, and combinations thereof, and (g) admixing the mixture remaining after step (f) with at least one immunogenic substance, different from said polypeptide.
• any of the herein described at least one immunogenic substance, different from said polypeptide, or component (ii), respectively, is used.
• said cells are preferably insect cells and said vector is preferably the baculovirus of the present disclosure.
• step (b) of said method said polypeptide is most preferably recovered in the supernatant of said cultured cells, rather than from inside the cells.
• the present invention provides the immunogenic composition of the present invention and the use of said immunogenic composition in any of the herein described methods, wherein said immunogenic composition is obtainable by the aforementioned method of producing the immunogenic composition of the present invention.
• the rotavirus A VP4 sequence was originally obtained from a swine fecal sample which most closely matches GenBank sequence JX971567.1 and is classified as a P[7] genotype.
• VP4 amino acids 57-224 (SEQ ID NO:3), also named “AVP8” hereinafter, were used and correspond to the lectin-like domain of the VP8 protein but with an N-terminus extended by eight amino acid residues.
• the linker moiety is Gly-Gly-Ser (SEQ ID NO:9).
• the Swine IgG Fc sequence matches amino acids 242-470 of IgG heavy chain constant precursor (GenBank sequence BAM75568.1).
• AVP8-lgG Fc The protein (SEQ ID NO: 12) encoded by AVP8-lgG Fc is also termed “AVP8-lgG Fc protein” herein.
• AVP8-lgG Fc was TOPO cloned and subsequently inserted into baculovirus transfer plasmid pVL1393 using the BamHI and Notl restriction sites, then co-transfected into Sf9 cells with BaculoGold to generate recombinant baculoviruses.
• Production of AVP8-lgG Fc protein was done as follows: 1 L of Sf+ cells in a 3L spinner flask was infected at 0.2MQI with spent media harvested 4DPI, centrifuged 20 minutes at 15,000g, and 0.2pm filtered.
• Protein-A purified AVP8-lgG Fc protein was formulated with Emulsigen D with 87.5% antigen and 12.5% adjuvant. Pigs of approximately seven weeks of age received a 2mL dose by IM on the side of the neck, with a boost 21 days later. Sera samples were collected weekly for seven weeks. Serum from pigs vaccinated with AVP8-lgG Fc protein were assessed by ELISA (Fig. 1), as described below (“Protocol for ELISA”), and virus neutralization assay (Fig. 2), as described below (“Protocol for virus neutralization assay”).
• the IgG ELISA results from pigs vaccinated with AVP8-lgG Fc protein showed an increase in SP ratio peaking at day 14 and rising again after the boost on day 21.
• Virus neutralization titers similarly showed an increase on days 7 and 14, followed by a second peak on day 28 following the boost on day 21 .
• IgA ELISA medium protein binding 96-well ELISA plates were coated with whole rotavirus antigen diluted in 1x PBS 1 :16. Plates were incubated at a temperature of 4°C overnight. Following incubation, plates were washed using 1x PBST and then blocked with Casein blocking solution for 1 hour @ 37°C. Following washing, 100 pL of primary antibodies diluted to a final dilution of 1 :40 in blocking buffer were added to plates and incubated for 1 hour @ 37°C.
• IgG ELISA medium protein binding 96-well ELISA plates were coated with whole rotavirus antigen diluted in 1x PBS 1 :8. Plates were incubated at a temperature of 4°C overnight. Following incubation, plates were washed using 1x PBST and then blocked with Blotting grade blocking solution for 1 hour @ 37°C. Following washing, 100 pL of primary antibodies diluted to a final dilution of 1 :625 in blocking buffer were added to plates and incubated for 1 hour @ 37°C.
• the primary antibody (Rabbit anti- Rotavirus A polyclonal serum, internally generated) was diluted 1 :1000 in 1X PBS. 100pL/well of the diluted primary antibody was added and plates were incubated at 37°C ⁇ 5% CO2 for one hour. Following incubation, plates were washed twice with 100pL/well of 1X PBS.
• the secondary antibody (Jackson ImmunoResearch FITC labeled goat-anti-rabbit IgG cat# 111-095-003) was diluted 1 :100 in 1X PBS. 100pL/well of the diluted secondary antibody was added and plates were incubated at 37°C ⁇ 5% CO2 for one hour.
• the primary purpose of this study was to evaluate whether administration of a prototype vaccine, also termed “lgG:AVP8” herein, including AVP8-lgG Fc protein (SEQ ID NO:12) and a non-relevant control vaccine, termed “Placebo” herein, to conventional sows conferred passive protection to pigs against a virulent rotavirus A challenge.
• a commercially available MLV rotavirus vaccine (ProSystem® Rota, Merck Animal Health), also termed “commercial product” or “Commercial vaccine” herein, was used in the study.
• the prototype vaccine was produced similarly to the production described above in Example 1 , but with different volumes used for the infection and a longer incubation period, as described below in the section “Production oflgG:AVP8”.
• the commercial product was used according to the label instructions (dosage and directions, as well as the recommended Method for oral vaccination of swine) provided by the manufacturer for the vaccine ProSystem® TGE/Rota.
• Farrowing was allowed to occur naturally until the sow reached gestation day 114. After this time, farrowing was induced. Piglets were enrolled into the trial at the time of farrowing. Only piglets which were healthy at birth were tagged, processed according to facility standard operating procedures, and included in the trial. When pigs were zero to five days of age, they were bled, a fecal swab was collected, and pigs were challenged (excluding T07). At the time of challenge, pigs were administered an intragastric, 5m L dose of sodium bicarbonate, then an intragastric, 5m L dose of the challenge material. Throughout the challenge period, all animals were monitored daily for the presence of enteric disease (diarrhea, and behavior changes).
• T04 Prior to the time of pig challenge, 5/5 animals in T04 (lgG:AVP8) had a four-fold or greater increase in titer. Sows in the placebo group (T02) had no significant increase ( ⁇ 2-fold) in serum VN titer during the vaccination phase. Sows in T06 (Commercial vaccine), had no significant increase ( ⁇ 2-fold) in serum VN titer through D35. Prior to the time of pig challenge, both sows of T06 (Commercial vaccine) had a four-fold increase in titer. Following lateral exposure to challenge material, VN serum titers in sows in T02 (Placebo) and T06 (Commercial vaccine) increased.
• VN serum titers in sows in T04 remained constant or decreased in 4/5 sows.
• VN titers in group T04 (lgG:AVP8), VN titers were highest at farrowing, decreased in the pre-challenge sample and further decreased in the post-challenge sample.
• placebo group (T02) VN titers were low at farrowing and pre-challenge but increased following lateral exposure to the challenge material.
• VN titers in pig serum pre-challenge were high (>1280) in the majority of pigs in T04 (lgG:AVP8) indicating passive transfer of immunity from sows to pigs. Conversely, the majority of titers in pigs in T02 (Placebo) and T06 (Commercial vaccine) were low ( ⁇ 1280).
• Pigs from each group were euthanized and necropsied at DPC2. Pigs were evaluated for the presence of macroscopic enteric lesions (thin-walled, gas- distended small intestine, pure liquid content, etc), microscopic lesions (atrophic enteritis), and Rotavirus A specific staining by immunohistochemistry (IHC). Table 3 below presents the number of pigs with enteric lesions at the time of necropsy by group. The challenge was considered successful as 84.2% (16/19) of pigs in the placebo group (T02) had macroscopic lesions and of those 63.2% (12/19) had staining.
• IHC Immunhistochemistry
• Score 1 ⁇ 10% of villi contain antigen
• Score 2 10% to 50% of villi contain antigen
• Score 3 >50% of villi contain antigen Not applicable as pigs from T07 were not necropsied
• the average daily weight gain was calculated for surviving pigs (in kg) and is presented in Table 4 below.
• the highest numerical benefits in ADWG were observed in pigs from T04 (lgG:AVP8).
• the increase in ADWG following vaccination was significantly different in comparison to T02 (Placebo).
• Table 4 Mean average daily weight gain in kg (standard deviation) by group.
• pigs born to vaccinated sows had reduced fecal shedding of rotavirus A RNA, reduced mortality, reduced clinical signs of diarrhea, reduced colonization of rotavirus A at DPC2, reduced macroscopic lesions at DPC2, and increased ADWG as compared to pigs born to placebo controls and the commercially available vaccine.
• Real-time RT-PCR was carried out in a 20 l reaction containing 5pl of extracted total nucleic acid, I pl of each probe (5pM), 1 l of each primer (10pM), 10pl of 2X RT-PCR mix, 0.5 l iScript reverse transcriptase and 0.5 l of DEPC-treated water.
• the reaction took place using a CFX96 real-time PCR detection system (BioRad) under the following conditions: initial reverse transcription at 50°C for 10min, followed by initial denaturation at 95°C for 3 min, 40 cycles of denaturation at 95°C for 15s and annealing and extension at 60°C for 45s.
• 2L of Sf+ (Spodoptera frugiperda) cells at an approximate concentration of 1x10 6 cells/mL in a 5L shaker flask were infected with 1.7mL of a recombinant baculovirus stock containing the Rotavirus A VP8 core-swine IgG Fc fusion protein (BaculoGold (BG)/pVL1393-AVP8-lgG; 1.18x108 TCID50/mL).
• the shaker flask was incubated at 28°C ⁇ 2°C with constant agitation at 90rpm for five days.
• Cells and media were aseptically transferred to 3 x 1 L centrifuge bottles and cells were pelleted at 10,000g for 20 minutes at 4°C.
• the resulting supernatant was passed through a 0.2pm filter (Thermo Scientific, cat# 567-0020) then incubated with 2.5mL of MabSelect SuRe LX protein A resin (GE Healthcare cat# 17-5474-01) overnight at 4°C with moderate stirring. Resin was recovered by 0.2pm filtration (Thermo Scientific, cat# 567-0020) then washed with 12 x 10mL volumes of Gentle Ag/Ab Binding Buffer (Thermo Scientific, cat# 21012). AVP8-lgG was eluted from the resin using 7 x 10mL volumes of Gentle Ag/Ab Elution Buffer (Thermo Scientific, cat# 21027).
• AVP8-lgG was dialyzed against 3.5L of 20mM Tris pH 7.5, 150mM NaCI with one buffer change. Residual baculovirus was inactivated with 5mM BEI for 24 hours at 37°C. The resulting material was diluted to a target concentration of 70pg/mL in 1x PBS (Gibco cat#10010-023). The diluted material was formulated with 12.5% Emulsigen D.
• the primary purpose of this study was to evaluate whether administration of a prototype vaccine including AVP8-lgG Fc protein (SEQ ID NO:12)) and a control vaccine, termed “Placebo” herein, to conventional sows generated a serological response against rotavirus A.
• the prototype vaccine (either comprising Emulsigen D or Carbopol as an adjuvant, c.f. Tables 7 A and 7 B below), also termed “lgG-AVP8” herein, was produced similarly to the production described above in Examples 1 and 2, but with different volumes used for the infection and a longer incubation period, as described below in the section “Vaccine Production: lgG-AVP8".
• the primary purpose of this study was to evaluate whether animals vaccinated with lgG-AVP8 (including AVP8-lgG Fc protein (SEQ ID NO: 12)) would be able to cross neutralize various Rotavirus A serotypes/genotypes of various G and P types other than P[7], from which the AVP8-lgG Fc protein was designed. This would indicate the ability of the AVP8-lgG Fc protein (SEQ ID NO: 12) to be protective against other isolates.
• heat inactivated serum from pigs vaccinated with lgG-AVP8 was diluted 2-fold starting at 1:200 in MEM in a dilution block from Row A to Row G.
• Row H contained no serum.
• Rotavirus A of various G and P types was diluted 1.5 fold across dilution plate starting at 6.0 LogioTCIDso/mL from column 1 to column 11.
• Column 12 contained no virus. 250pL of virus and 250pL of serum from corresponding wells were combined and incubated for 1 hour at 37°C.
• animals vaccinated with lgG-AVP8 (including AVP8-lgG Fc protein (SEQ ID NO: 12)) will cross neutralize rotavirus genotypes P[7] and P[23], G type played no significant role in the neutralization of virus.
• Pigs are randomized into four treatment groups with 10 pigs per group. Pigs are comingled throughout the study. General health observations, prescreen serum samples, and prescreen fecal samples are taken prior to treatment to confirm the health of animals, determine baseline serological response to rotavirus A, and to confirm no active rotavirus A infection prior or at the time of vaccination.
• mice are vaccinated intramuscularly with the following materials: T01 : lgG-P[7]AVP8 vaccine (comprising the polypeptide of SEQ ID NO:12), T02: lgG-P[13]AVP8 vaccine (comprising the polypeptide of SEQ ID NO:14), T03: P[7]AVP8-lgG-P[13]AVP8 vaccine (comprising the polypeptide of SEQ ID NO:16), T04: placebo. Serum samples are taken on study days 0, 7, 14, 21 , 28, 36, 42, and 49. All animals are humanely euthanized on study D49 at necropsy.
• Serum samples are tested by a virus neutralization assay to determine the serological response to vaccine prototypes over time.
• Animals vaccinated with T01 have antibodies neutralizing rotavirus genotypes P[7] and P[23]
• animals vaccinated with T02 have antibodies neutralizing rotavirus genotype P[13]
• animals vaccinated with T03 have antibodies neutralizing rotavirus genotypes P[7], P[13] and P[23],
• SDS-PAGE of protein A purified AVP8-lgG Fc protein (SEQ ID NO: 12) product with and without DTT (Fig. 5 A)): The method to generate the samples for the SDS-PAGE image was briefly as follows: baculovirus harvest supernatant was inactivated with 10mM BEI at 37°C for 36 hours and then neutralized. The sample was then purified using protein A resin. All samples were then denatured using NuPAGE 4x LDS sample buffer (Invitrogen cat# NP0007) with either 25mM DTT (final) or equal volume of water, and heated at 95C for 10 minutes.
• Anti-swine IgG Fc fragment Western Blot (Fig. 5 B): AVP8-lgG Fc protein (SEQ ID NO:12) product that had been produced in a bioreactor was harvested with a 1mL sample prior to BEI addition. The sample was centrifuged at 20,000g and 4°C for 5 minutes, supernatant decanted to a fresh tube, and both pellet and supernatant stored at -70C. Pellet and supernatant were thawed, pellet resuspended in 1 mL of 8M urea, then equal amounts of pellet and supernatant were run out on SDS-PAGE under reducing conditions (+DTT), and transferred to a PVDF membrane. Western blot was probed with 1 :1000 dilution of HRP conjugated goat anti-swine to detect swine IgG Fc fragment.
• Sequences were compiled from publically available swine rotavirus VP4 nucleotide sequences from the NCBI Virus Variation database and internally derived rotavirus isolate sequences. Additional metadata for sequences was also compiled including metadata for: isolate name, isolate P-Type, Geographic Origin, and date of isolation when available. Nucleotide sequences were translated into protein sequences, and aligned to known VP8 proteins using MUSCLE sequence alignment software UPGMB clustering and default gap penalty parameters. Unaligned VP5 amino acids were trimmed and discarded. VP8 aligned protein sequences were imported into MEGA7 software for phylogenetic analysis and a neighbor joining phylogeny reconstruction was generated based on VP8 protein sequence.
• the primary purpose of this study was to evaluate whether administration of a prototype vaccine, also termed “lgG#AVP8” herein, including AVP8-lgG Fc protein (SEQ ID NO: 12) and a non-relevant control vaccine, termed “Placebo” herein, to conventional dams conferred passive protection to pigs against a virulent rotavirus A challenge.
• the prototype vaccine was produced similarly to the production described above in Example 1 , but with different volumes used for the infection and a different purification method, as described below in the section “Production of lgG#AVP8".
• Dams in T01 and T03 were comingled between three rooms. Dams in T07 were housed in a separate room. All dams were vaccinated with the appropriate material by the appropriate route as listed in Table 9. Dams in T07 remained non-vaccinated (strict control). Serum was collected from the dams periodically throughout the vaccination period and assayed for evidence of seroconversion. Fecal samples were collected prior to farrowing and screened by RT-qPCR to confirm dams were not actively shedding rotavirus prior to farrowing. General health observations were recorded on each sow daily.
• dams in group T01 had a significant increase ( ⁇ 2-fold) in serum VN titer during the vaccination phase.
• Dams colostrum VN titers dams in group T03 (lgG#AVP8) had a higher mean VN titer in comparison to dams in group T01 (Placebo).
• VN titers in pig serum pre-challenge were high (>1280) in the majority of pigs in group T03 (lgG#AVP8) indicating passive transfer of immunity from dams to pigs. Conversely, the majority of titers in pigs in T02 (Placebo) were low ( ⁇ 1280).
• a pig was defined as affected if rotavirus antigen was detected by immunohistochemistry (IHC) in at least one intestinal section and the animal had an abnormal fecal score for at least one day post-challenge.
• IHC immunohistochemistry
• the frequency distributions are listed in Table 11 below. Based on the use of this case definition, vaccination of dams at 6 and 2 weeks pre-farrow with the prototype vaccine lgG#AVP8 (group T03) prevented rotavirus associated disease in pigs following challenge with heterologous rotavirus A P[7] challenge material; preventative fraction 0.926, 95% confidence interval 0.734, 0.979.
• the clarified supernatant (8L/vessel) was inactivated with 5mM BEI for three days at 37°C in the Sartorius Biostat B glass-jacketed vessels. Following inactivation, residual BEI was neutralized with sodium thiosulfate. Following neutralization, 7000m L was concentrated approximately 10x using a 10kDa hollow fiber filter (GE, cat# UFP-10-C-5A) to 700 mL. Concentrated material was diafiltrated with 5 volumes (3500mL) of 1x PBS. The vaccine was formulated with 12.5% Emulsigen D, 28% concentrated material, and 59.5% 1x PBS (volume:volume).
• mice A total of 20 animals are used in this study. Pigs are randomized into two treatment groups with 10 pigs per group. Pigs are comingled throughout the study. General health observations, prescreen serum samples, and prescreen fecal samples are taken prior to treatment to confirm the health of animals, determine baseline serological response to rotavirus C, and to confirm no active rotavirus C infection prior or at the time of vaccination. On study day zero (DO) and D28, animals are vaccinated intramuscularly with the following materials: T01 : lgG-CVP8 vaccine (comprising the polypeptide of SEQ ID NO: 15), T02: placebo. Serum samples are taken on study days 0, 7, 14, 21 , 28, 36, and 42.
• mice All animals are humanely euthanized on study D42 at necropsy. Serum samples are tested by an ELISA to determine the serological response to vaccine prototypes over time. Animals vaccinated with T01 have a higher mean level of antibodies against rotavirus C than the animals vaccinated with T02, which do not have an increase in titer.
• the primary purpose of this study was to evaluate whether administration of a prototype vaccine, also termed “lgG:AVP8 P[6,7, 13]” herein, which included three AVP8-lgG Fc proteins (SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14) and a non-relevant control vaccine, termed “Placebo” herein, to conventional dams conferred passive protection to pigs against a virulent rotavirus A challenge.
• the components of the prototype vaccine were produced similarly to the production described above in Example 1 and were subsequently mixed, as described below in the section “Production of lgG:AVP8 P[6, 7, 13J’.
• Dams in T01 and T03 were commingled between seven rooms.
• Dams in T04 were housed in a separate room. All dams were vaccinated with the appropriate material by the appropriate route as listed in Table 12. Dams in T04 remained non-vaccinated (strict control). Serum was collected from the dams periodically throughout the vaccination period and assayed for evidence of seroconversion by virus neutralization (VN) and enzyme-linked immunosorbent assay (ELISA). Fecal samples were collected prior to farrowing and screened by RT-qPCR to confirm dams were not actively shedding rotavirus prior to farrowing.
• VN virus neutralization
• ELISA enzyme-linked immunosorbent assay
• RT-qPCR was conducted as described above in Example 2 (“Protocol for Rota A qRT-PCR”). General health observations were recorded on each sow daily. Farrowing was allowed to occur naturally until the sow reached gestation day 115. After this time, farrowing was induced. Piglets were enrolled into the trial at the time of farrowing. Only piglets which were healthy at birth were tagged, processed according to facility standard operating procedures, and included in the trial. When pigs were two to five days of age, they were bled, a fecal swab was collected, and pigs were challenged (excluding T04).
• VN titers in pig serum pre-challenge were high (>1280) in the majority of pigs in group T03 (lgG:AVP8 P[6,7, 13]) indicating passive transfer of immunity from dams to pigs. Conversely, none of the VN titers in pigs in T01 (Placebo) were high (>1280).
• a pig was defined as affected if rotavirus antigen was detected by immunohistochemistry (IHC) in at least one intestinal section and the animal had an abnormal fecal score for at least one day post-challenge.
• IHC immunohistochemistry
• the prototype vaccine contained three fractions. The production of each fraction was done separately and is described below.
• the vaccine was formulated with 12.0% Emulsigen D, 7% lgG:AVP8 P[7] fraction, 4.4% lgG:AVP8 P[6] fraction, 1.8% lgG:AVP8 P[13] fraction, and 47.8% 1x PBS (volume:volume).
• lgG:AVP8 P[7] fraction One 10L Sartorius Biostat B glass-jacketed vessels was seeded with 3L of Sf+ cells at 0.75x10 A 6 cells/mL.
• the vessel was infected at an MOI of 0.1 and the volume of the vessel was adjusted to 8L using Ex-cell 420 serum free medium (SAFC cat#14420C-1000mL).
• SAFC serum free medium
• the bioreactor was run at 27°C with 100 rpm agitation, with the dissolved oxygen set at or above 40%, and a CCA overlay at 1.3slpm.
• the vessel was harvested at 7 days post inoculation; fluids were centrifuged at 10,000g at 4°C for 20 minutes, and supernatant was 0.8/0.2pm filtered (GE Healthcare, cat# 6715-7582).
• the clarified supernatant (8L/vessel) was inactivated with 5mM BEI for three days at 37°C in the Sartorius Biostat B glass-jacketed vessels. Following inactivation, residual BEI was neutralized with sodium thiosulfate. Following neutralization, approximately 7000mL was concentrated approximately 10x using a 10kDa hollow fiber filter (GE, cat# UFP-10-C-5A) to 700 mL. Concentrated material was diafiltrated with 5 volumes (3500mL) of 1x PBS. lgG:AVP8 P[6] fraction: One 10L Sartorius Biostat B glass-jacketed vessels was seeded with 3L of Sf+ cells at 0.75x10 A 6 cells/mL.
• the vessel was infected at an MOI of 0.1 and the volume of the vessel was adjusted to 8L using Ex-cell 420 serum free medium (SAFC cat#14420C-1000mL).
• SAFC serum free medium
• the bioreactor was run at 27°C with 100 rpm agitation, with the dissolved oxygen set at or above 40%, and a CCA overlay at 1.3slpm.
• the vessel was harvested at 8 days post inoculation; fluids were centrifuged at 10,000g at 4°C for 20 minutes, and supernatant was 0.8/0.2pm filtered (GE Healthcare, cat# 6715-7582).
• the clarified supernatant (8L/vessel) was inactivated with 10mM BEI for 24 hours at 37°C in the Sartorius Biostat B glass-jacketed vessels. Following inactivation, residual BEI was neutralized with sodium thiosulfate. Following neutralization, approximately 7000mL was concentrated approximately 10x using a 10kDa hollow fiber filter (GE, cat# UFP-10-C-5A) to 600 mL. Concentrated material was diafiltrated with 5 volumes (3500mL) of 1x PBS. lgG:AVP8 P[13] fraction: One 10L Sartorius Biostat B glass-jacketed vessels was seeded with 3L of Sf+ cells at 0.75x10 A 6 cells/mL.
• the vessel was infected at an MOI of 0.1 and the volume of the vessel was adjusted to 8L using Ex-cell 420 serum free medium (SAFC cat#14420C-1000mL).
• SAFC serum free medium
• the bioreactor was run at 27°C with 100 rpm agitation, with the dissolved oxygen set at or above 40%, and a CCA overlay at 1.3slpm.
• the vessel was harvested at 7 days post inoculation; fluids were centrifuged at 10,000g at 4°C for 20 minutes, and supernatant was 0.8/0.2pm filtered (GE Healthcare, cat# 6715-7582).
• the clarified supernatant (8L/vessel) was inactivated with 10mM BEI for 24 hours at 37°C in the Sartorius Biostat B glass-jacketed vessels. Following inactivation, residual BEI was neutralized with sodium thiosulfate. Following neutralization, approximately 7000mL was concentrated approximately 10x using a 10kDa hollow fiber filter (GE, cat# UFP-10-C-5A) to 750 mL. Concentrated material was diafiltrated with 5 volumes (3500mL) of 1x PBS.
• Nuc MaxiSorb 96-well ELISA plates (Thermo) were coated with Rotavirus A VP8 P[13] purified protein diluted in 1x PBS 1 :10. Plates were incubated at 37°C for 1 hour. Following incubation, plates were washed using 1x PBST and then blocked with 3%BSA in PBST for 1 hour at 37°C. Following washing, 100 pL of test sera diluted to a final dilution of 1 :512 in 1x PBS were added to plates and incubated for 1 hour at 37°C.
• Nuc MaxiSorb 96-well ELISA plates (Thermo) were coated with Rotavirus A VP8 P[6] purified protein diluted in 1x PBS 1 :10. Plates were incubated at 37°C for 1 hour. Following incubation, plates were washed using 1x PBST and then blocked with 3%BSA in PBST for 1 hour at 37°C. Following washing, 100 pL of test sera diluted to a final dilution of 1 :512 in 1x PBS were added to plates and incubated for 1 hour at 37°C.
• Growth media was aseptically removed from three-four day old 96-well plates planted with MA104 cells. Following incubation, 200pl of the virus-serum mixture was transferred to the cell culture plates. Cells were incubated at 37°C ⁇ 5% CO2 for 3-4 days. The stock and diluted virus were titrated on the day of use to confirm the dilution used in the assay. Following incubation, the supernatant was discarded. For fixation, 100pL/well of 50%/50% acetone/methanol was added. Plates were incubated at room temperature for 15 minutes, airdried, then rehydrated with 100pL/well 1X PBS.
• the primary antibody (Rabbit anti-Rotavirus A polyclonal serum, internally generated) was diluted 1 :1000 in 1X PBS. 100pL/well of the diluted primary antibody was added and plates were incubated at 37°C ⁇ 5% CO2 for one hour. Following incubation, plates were washed twice with 100pL/well of 1X PBS.
• the secondary antibody (Jackson ImmunoResearch FITC labeled goat-anti-rabbit IgG cat# 111- 095-003) was diluted 1 :100 in 1X PBS. 100pL/well of the diluted secondary antibody was added and plates were incubated at 37°C ⁇ 5% CO2 for one hour.
• the primary purpose of this study is to evaluate whether administration of a prototype vaccine, also termed “lgG:AVP8 P[6,7,13] + lgG:CVP8” herein, which includes three AVP8-lgG Fc proteins (SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14) and one CVP8-lgG Fc protein (SEQ ID NO: 15) and a non-relevant control vaccine, termed “Placebo” herein, to conventional dams confers passive protection to pigs against a virulent rotavirus A challenge. A total of 24 dams are included in the study. Dams are randomized into two treatment groups and one strict control group as described in Table 15 below.
• Dams in T01 and T02 are comingled between three rooms. Dams in T03 are housed in a separate room. All dams are vaccinated with the appropriate material by the appropriate route as listed in Table 15. Dams in T03 remain nonvaccinated (strict control). Serum is collected from the dams periodically throughout the vaccination period and assayed for evidence of seroconversion. Fecal samples are collected prior to farrowing and screened by RT-qPCR to confirm dams are not actively shedding rotavirus prior to farrowing. General health observations are recorded on each sow daily. Farrowing is allowed to occur naturally until the sow reaches gestation day 114. After this time, farrowing is induced. Piglets are enrolled into the trial at the time of farrowing.
• Dams in group T01 (lgG:AVP8 P[6,7,13] + lgG:CVP8) have a higher mean level of antibodies against rotavirus A genotype P[6], P[7], and P[13] and rotavirus C than the animals vaccinated with T02 (Placebo), which do not have an increase in titer.
• Dams in group T01 (lgG:AVP8 P[6,7,13] + lgG:CVP8) have fewer affected piglets (as determined by clinical signs and immunohistological evaluation) as compared to dams in group T02 (Placebo).
• Fig. 1 Serum IgG response of pigs, either vaccinated with AVP8-lgG Fc protein formulated with Emulsigen D (termed “AVP8-lgG” in the labelling) or with Placebo (“Non-relevant control”), directed against porcine rotavirus A.
• Fig. 2 Results of a VN (virus neutralization) assay conducted for detecting and quantifying antibodies being capable to neutralize porcine rotavirus A virus, in samples of pigs vaccinated with AVP8-lgG Fc protein formulated with Emulsigen D (termed “AVP8-lgG” in the labelling) or with Placebo (”Non-relevant control”).
• VN virus neutralization
• Fig. 3 Mean VN titers against rotavirus in sow serum by group and study day, wherein study days DO and D28 represent the time points “six weeks and two weeks pre-farrow” (i.e. when investigational products were administered to study group T02 and T04, respectively) and study days D7, D28 and D35 represent the time points “five weeks, two weeks and one week pre-farrow” (i.e. when Commercial vaccine was administered to T06).
• Fig. 4 Group median log rotavirus A RNA genomic copies (gc)/mL in feces by study day.
• Fig. 5 A) SDS-PAGE of protein A purified AVP8-lgG Fc protein (SEQ ID NO: 12) product samples being either reduced with Dithiothreitol (“+DTT”) or non-reduced (“-DTT”); B) Western Blot of AVP8-lgG Fc protein (SEQ ID NO:12) bioreactor product, wherein a sample was centrifuged to separate a cell pellet fraction (“Pellet”) and a supernatant fraction (“Supernatant”), which after a freeze-thaw process were run out on SDS-PAGE under reducing conditions (+DTT), transferred to a PVDF membrane and probed with HRP conjugated goat anti-swine to detect swine IgG Fc fragment.
• Pellet cell pellet fraction
• Supernatant supernatant
• Fig. 6 Mean VN titers against rotavirus in sow serum by group and study day, wherein study days DO and D28 represent the time points “six weeks and two weeks pre-farrow” (i.e. when investigational products were administered to study group T01 and T03, respectively).
• Fig. 7 Mean VN titers against rotavirus in sow serum by group and study day, wherein study day DO represents the time point of the first administration of the investigational products to study group T01 and T03, respectively.
• Fig. 8 Results of “lgG:AVP8 P[6] ELISA”, wherein ELISA plates coated with Rotavirus A VP8 P[6] protein were incubated with diluted test sera, and wherein anti-Rotavirus AVP8 P[6] antibodies were then detected by using HRP-conjugated-goat-anti-swine-IgG antibody.
• Fig. 9 Results of “lgG:AVP8 P[13] ELISA”, wherein ELISA plates coated with Rotavirus A VP8 P[13] protein were incubated with diluted test sera, and wherein anti-Rotavirus AVP8 P[13] antibodies were then detected by using HRP-conjugated-goat-anti-swine-IgG antibody.
• SEQ ID NO:1 corresponds to the seguence of a (genotype P[7]) rotavirus VP8 protein, sourced from a farm in North Carolina, USA,
• SEQ ID NO:2 corresponds to the seguence of a lectin-like domain of a (genotype P[7]) rotavirus VP8 protein, sourced from a farm in North Carolina, USA
• SEQ ID N0:3 corresponds to the sequence of an immunogenic fragment of a (genotype P[7]) rotavirus VP8 protein, sourced from a farm in North Carolina, USA
• SEQ ID NO:4 corresponds to the sequence of an immunogenic fragment of a rotavirus VP8 protein, i.e. a consensus sequence of a portion of rotavirus VP8 protein (based on genotype P[6])),
• SEQ ID NO:5 corresponds to the sequence of an immunogenic fragment of a rotavirus VP8 protein, i.e. a consensus sequence of a portion of an immunogenic fragment of rotavirus VP8 protein (based on genotype P[13]),
• SEQ ID NO:6 corresponds to the sequence of an immunogenic fragment of a rotavirus C VP8 protein
• SEQ ID NO:7 corresponds to the sequence of a swine IgG Fc fragment
• SEQ ID NO:8 corresponds to the sequence of a guinea pig IgG Fc fragment
• SEQ ID NO:9 (Gly-Gly-Ser) corresponds to the sequence of a linker moiety
• SEQ ID NO: 10 corresponds to the sequence of a linker moiety
• SEQ ID NO:11 corresponds to the sequence of a linker moiety
• SEQ I D NO: 12 corresponds to the sequence of a polypeptide (fusion protein) which comprises the sequences of SEQ ID NO:3, SEQ ID NO:9 (Gly-Gly-Ser), and SEQ ID NO:7,
• SEQ I D NO: 13 corresponds to the sequence of a polypeptide (fusion protein) which comprises the sequences of SEQ ID NO:4, SEQ ID NO:9 (Gly-Gly-Ser), and SEQ ID NO:7,
• SEQ I D NO: 14 corresponds to the sequence of a polypeptide (fusion protein) which comprises the sequences of SEQ ID NO:5, SEQ ID NO:9 (Gly-Gly-Ser), and SEQ ID NO:7,
• SEQ I D NO: 15 corresponds to the sequence of a polypeptide (fusion protein) which comprises the sequences of SEQ ID NO:6, SEQ ID NO:9 (Gly-Gly-Ser), and SEQ ID NO:7,
• SEQ I D NO: 16 corresponds to the sequence of a polypeptide (fusion protein) which comprises the sequences of SEQ ID NO:3, SEQ ID NO:9 (Gly-Gly-Ser), SEQ ID NO:7, SEQ ID NQ:10, and SEQ ID NO:5, SEQ ID NO: 17 corresponds to the sequence of a polynucleotide encoding the polypeptide (fusion protein) of SEQ ID NO:12,
• SEQ ID NO: 18 corresponds to the sequence of a polynucleotide encoding the polypeptide (fusion protein) of SEQ ID NO: 13,
• SEQ ID NO: 19 corresponds to the sequence of a polynucleotide encoding the polypeptide (fusion protein) of SEQ ID NO: 14,
• SEQ ID NQ:20 corresponds to the sequence of a polynucleotide encoding the polypeptide (fusion protein) of SEQ ID NO: 15,
• SEQ ID NO:21 corresponds to the sequence of a polynucleotide encoding the polypeptide (fusion protein) of SEQ ID NO: 16,
• SEQ ID Nos:22-25 primer and probe sequences (Table 5).
• An immunogenic composition which comprises
• immunogenic composition of any one of clauses 1 to 5 wherein said immunoglobulin Fc fragment is linked to the C-terminus of said immunogenic fragment of a rotavirus VP8 protein via a linker moiety, or wherein said immunoglobulin Fc fragment is linked to the C-terminus of said immunogenic fragment of a rotavirus VP8 protein via a peptide bond between the N- terminal amino acid residue of said immunoglobulin Fc fragment and the C-terminal amino acid residue of said immunogenic fragment of a rotavirus VP8 protein.
• the immunogenic composition of any one of clauses 1 to 8 wherein said immunogenic fragment of a rotavirus VP8 protein is capable of inducing an immune response against rotavirus in a subject to whom said immunogenic fragment of a rotavirus VP8 protein is administered.
• the immunogenic composition of any one of clauses 1 to 10 wherein said rotavirus is porcine rotavirus.
• the immunogenic composition of clause 14 or 15, wherein the lectin-like domain of a rotavirus VP8 protein consists of the amino acid sequence of the amino acid residues 65-224 of a rotavirus VP8 protein.
• immunogenic fragment of a rotavirus C VP8 protein as specified in any one of clauses 9 to 12, 27 and 28.
• immunogenic composition of any one of clauses 1 to 31 wherein said immunoglobulin Fc fragment comprises or consists of the heavy-chain constant region 2 (CH2) and the heavy-chain constant region 3 (CH3), and optionally the hinge region or a part of the hinge region, of an immunoglobulin.
• immunogenic composition of any one of clauses 1 to 35 wherein said immunoglobulin Fc fragment comprises or consists of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:8.
• linker moiety is an amino acid sequence being 1 to 50 amino acid residues in length.
• SEQ ID NO:9 Gly-Gly-Ser
• SEQ ID NQ:10 SEQ ID NO:11
• SEQ ID NO:11 amino acid sequence having at least 66%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:9 (Gly-Gly-Ser), SEQ ID NQ:10 and SEQ ID NO:11.
• SEQ ID NO:9 Gly-Gly-Ser
• SEQ ID NQ:10 SEQ ID NO:11
• said further immunogenic fragment of a rotavirus VP8 protein comprises or consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 2 to 6, and/or wherein said further immunogenic fragment of a rotavirus VP8 protein is different from the immunogenic fragment of a rotavirus VP8 protein of which the C-terminus is linked to said immunoglobulin Fc fragment.
• an immunoglobulin Fc fragment in particular an immunoglobulin Fc fragment as specified in any one or more of clauses 31 to 36, wherein said immunoglobulin Fc fragment is linked to the C-terminus of said immunogenic fragment of a rotavirus VP8 protein, in particular via a linker moiety, wherein said linker moiety is preferably a linker moiety as specified in clause 37 or 38,
• component (ii) consists of at least one immunogenic substance which comprises a rotavirus antigen, different from said immunogenic fragment of component (i).
• component (ii) consists of two or more immunogenic substances, wherein each of said substances comprises a rotavirus antigen, and wherein all of said rotavirus antigens are different from said immunogenic fragment of component (i) and different from each other.
• component (ii) consists of at least one protein which comprises a rotavirus antigen, different from said immunogenic fragment of component (i).
• component (ii) consists of two or more proteins, wherein each of said proteins comprises a rotavirus antigen, and wherein all of said rotavirus antigens are different from said immunogenic fragment of component (i) and different from each other.
• component (ii) consists of two or more proteins, wherein each of said proteins comprises a rotavirus antigen, and wherein all of said rotavirus antigens are different from said immunogenic fragment of component (i) and different from each other.
• the immunogenic composition of clause 61 wherein said third polypeptide comprises a reovirus antigen, different from both said immunogenic fragment and reovirus antigen of the second polypeptide, and wherein optionally said fourth polypeptide comprises a reovirus antigen, different from all of said immunogenic fragment, the reovirus antigen of the second polypeptide and the reovirus antigen of the third polypeptide.
• the at least one immunogenic substance, different from said polypeptide comprises or consists of a second polypeptide comprising a second immunogenic fragment of a rotavirus VP8 protein, wherein said second immunogenic fragment is different from said first immunogenic fragment, and preferably a third polypeptide comprising a third immunogenic fragment of a rotavirus VP8 protein, wherein said third immunogenic fragment is different from both said first and second immunogenic fragment, and optionally a fourth polypeptide comprising a fourth immunogenic fragment of a rotavirus VP8 protein, wherein said fourth immunogenic fragment is different from all of said first to third immunogenic fragments.
• X7 represents an immunogenic fragment of a genotype P[7] rotavirus VP8 protein
• X13 represents an immunogenic fragment of a genotype P[13] rotavirus VP8 protein
• X6 represents an immunogenic fragment of a genotype P[6] rotavirus VP8 protein
• XC represents an immunogenic fragment of a rotavirus C VP8 protein.
• X7 consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:3, and/or
• X13 consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:5, and/or
• X6 consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:4, and/or XC consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:6.
• the immunogenic composition of one or more of clauses 65 to 71 wherein said first immunogenic fragment is an immunogenic fragment of a genotype P[7] rotavirus VP8 protein, and said second immunogenic fragment is an immunogenic fragment of a genotype P[13] rotavirus VP8 protein, and preferably said third immunogenic fragment is an immunogenic fragment of a genotype P[6] rotavirus VP8 protein, and and optionally said fourth immunogenic fragment is an immunogenic fragment of a rotavirus C VP8 protein.
• said first immunogenic fragment consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:3
• said second immunogenic fragment consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:5
• said third immunogenic fragment consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:4
• said fourth immunogenic fragment consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:6.
• R7 is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:12,
• R13 is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 14,
• R6 is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 13, and
• RC is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 15.
• the immunogenic composition of clause 74 or 75 wherein the at least one immunogenic substance, different from said polypeptide, comprises or consists of a second polypeptide of a rotavirus VP8 protein, and wherein each of said first and second polypeptide is individually selected from the group consisting of R7, R13 and R6, provided that when said first polypeptide is R7, then said second polypeptide is selected from the group consisting of R13 and R6, provided that when said first polypeptide is R6, then said second polypeptide is selected from the group consisting of R7 and R13, and provided that when said first polypeptide is R13, then said second polypeptide is selected from the group consisting of R7 and R6.
• An immunogenic composition in particular the immunogenic composition of any one of clauses 1 to 82, which comprises a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with the sequence of SEQ ID NO: 12, and a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:13 and SEQ ID NO:15.
• An immunogenic composition in particular the immunogenic composition of any one of clauses 1 to 83, which comprises a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with the sequence of SEQ ID NO: 12, and a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with the sequence of SEQ ID NO: 14.
• the immunogenic composition of clause 84 which comprises a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ I D NO: 13.
• the immunogenic composition of clause 84 or 85 which comprises a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ I D NO: 15.
• the immunogenic composition of any one of clauses 1 to 86, wherein the immunogenic composition further comprises a pharmaceutical- or veterinary-acceptable carrier or excipient.
• the immunogenic composition composition of any one of clauses 1 to 88 comprising a pharmaceutical- or veterinary-acceptable carrier or excipient, and optionally an adjuvant.
• the immunogenic composition of clause 88 or 89, wherein the adjuvant is an emulsified oil-in-water adjuvant.
• the immunogenic composition of clause 88 or 89, wherein the adjuvant is a carbomer.
• the immunogenic composition of any one of clauses 1 to 91 for use as a medicament.
• the immunogenic composition of any one of clauses 1 to 91 for use as a vaccine for use as a vaccine.
• the immunogenic composition of any one of clauses 1 to 91 for use in a method for inducing an immune response against rotavirus in a subject for use in a method of reducing or preventing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in a subject or for use in a method of treating or preventing an infection with rotavirus in a subject.
• the immunogenic composition according to clause 102, wherein said sow to which the immunogenic composition has been administered is a sow to which the immunogenic composition has been administered while said sow has been pregnant, in particular with said piglet.
• a method for the treatment or prevention of a rotavirus infection, the reduction, prevention or treatment of one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection, or the prevention or treatment of a disease caused by a rotavirus infection comprising administering the immunogenic composition of any one of clauses 1 to 91 to a subject.
• a method for inducing the production of antibodies specific for rotavirus in a sow wherein said method comprises administering the immunogenic composition of any one of clauses 1 to 91 to said sow.
• a method of reducing or preventing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in a piglet wherein said method comprises
• a method of reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in a piglet wherein the piglet is to be suckled by a sow to which the immunogenic composition of any one of clauses 1 to 91 has been administered.
• the immunogenic composition according to any one of clauses 96 to 103 or the method of any one of clauses 104 to 109, wherein said one or more clinical signs are selected from the group consisting of
• said rotavirus infection is an infection with genotype P[23] rotavirus and/or genotype P[7] rotavirus
• said infection with rotavirus is an infection with a genotype P[23] rotavirus and/or genotype P[7] rotavirus
• said immune response against rotavirus is an immune response against genotype P[23] rotavirus and/or genotype P[7] rotavirus, or
• said antibodies specific for rotavirus are antibodies specific for genotype P[23] rotavirus and/or genotype P[7] rotavirus.
• immunogenic composition according to clause 113, wherein said immunogenic fragment of a genotype P[7] rotavirus VP8 protein consists of an amino acid sequence having at least 90%, preferably at least 95%, more preferably at least 98% or still more preferably at least 99% sequence identity with the sequence of SEQ ID NO:3.
• step (c) inactivating the vector by adding binary ethylenimine (BEI) to the mixture of step (b);
• step (d) neutralizing the BEI by adding sodium thiosulfate to the mixture resulting from step (c);
• step (e) concentrating the polypeptide in the mixture resulting from step (d) by removing a portion of the liquid from the mixture by a filtration step utilizing a filter with a filter membrane having a molecular weight cut off of between about 5 kDa and about 100 kDa, preferably between about 10 kDa and about 50 kDa; and wherein said method comprises the steps of
• step (f) admixing the mixture remaining after step (e) with a further component selected from the group consisting of pharmaceutically acceptable carriers, adjuvants, diluents, excipients, and combinations thereof, and
• step (g) admixing the mixture remaining after step (f) with at least one immunogenic substance, different from said polypeptide.
• said at least one immunogenic substance is the at least one immunogenic substance as specified in any one of clauses 50 to 76.
• step (a) the polypeptide as specified in any one of clauses 1 to 48 is a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 12.
• said at least one immunogenic substance, different from said polypeptide is at least one protein selected from the group consisting of a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:14, a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 13, and a protein comprising or consisting of an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 90%, still more preferably at least 95% or in particular 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 15.
• Vai Thr lie Asn Pro Gly Pro Phe Ala Gin Thr Gly Tyr Ala Pro Vai 35 40 45
• Gin Thr Thr Asn Arg lie Tyr Asn Leu Phe Gly Gin Gin Vai Thr Leu
• Gin Thr Thr Asn Arg lie Tyr Asn Leu Phe Gly Gin Gin Vai Thr Leu
• Glu Gly Vai lie lie Gin Gly Thr Asn Asn Thr Asp Arg Trp Leu Ala
• Gin Trp Lys Phe lie Asp Vai Ser Thr Thr Thr Pro Thr Gly Ser Tyr
• Lys Phe Ser Gly Arg lie Tyr Thr Tyr Ser Gly Thr Thr Pro Asn Ala
• Ser Phe Lys Pro Pro Asn Asp Tyr Trp lie Leu Leu Asn Pro Thr Asn
• Gin Gin lie Vai Leu Glu Gly Thr Asn Arg Thr Asp Vai Trp Vai Ala
• Leu Leu Leu lie Glu Pro Asn Vai Thr Asn Gin Ser Arg Gin Tyr Thr
• 35 40 45 lie lie Leu lie Glu Pro Asn Vai Pro Gin Glu Leu Arg Thr Tyr Thr
• Cys Pro lie Cys Pro Ala Cys Glu Ser Pro
• Ser Lys Vai Ser Vai Thr Cys Leu lie lie Asn Phe Phe Pro Ala Asp
• Tyr Lys Asn Thr Pro Pro lie Glu Asp Ala Asp Gly Ser Tyr Phe Leu
• Lys Ala lie Ser Arg Ser Pro Gly Lys
• Vai lie Gly Phe Tyr Pro Pro Asp lie Asp Vai Glu Trp Gin Arg Asn
• Vai Ser Vai Leu Pro lie Gin His Gin Asp Trp Leu Asn Gly Lys Glu
• 275 280 285 lie lie Ser Lys Ala Lys Gly Gin Thr Arg Glu Pro Gin Vai Tyr Thr

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Virology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Microbiology (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Oncology (AREA)
• Wood Science & Technology (AREA)
• Communicable Diseases (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biochemistry (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biotechnology (AREA)
• Gastroenterology & Hepatology (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biomedical Technology (AREA)
• General Engineering & Computer Science (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=86286035

Family Applications (1)

Country Status (13)

Families Citing this family (1)

Citations (36)

Family Cites Families (1)

• 2023
  • 2023-04-04 WO PCT/IB2023/053433 patent/WO2023194913A1/en not_active Ceased
  • 2023-04-04 CA CA3255048A patent/CA3255048A1/en active Pending
  • 2023-04-04 US US18/295,675 patent/US20240050555A1/en active Pending
  • 2023-04-04 JP JP2024559187A patent/JP2025511739A/ja active Pending
  • 2023-04-04 AU AU2023251268A patent/AU2023251268A1/en active Pending
  • 2023-04-04 AR ARP230100839A patent/AR128992A1/es unknown
  • 2023-04-04 KR KR1020247036936A patent/KR20240170836A/ko active Pending
  • 2023-04-04 CN CN202380032319.XA patent/CN119894528A/zh active Pending
  • 2023-04-04 EP EP23720982.0A patent/EP4504251A1/en active Pending
  • 2023-04-06 TW TW112112876A patent/TW202404629A/zh unknown
• 2024
  • 2024-10-04 CL CL2024003001A patent/CL2024003001A1/es unknown
  • 2024-10-04 MX MX2024012371A patent/MX2024012371A/es unknown
  • 2024-10-04 CO CONC2024/0013522A patent/CO2024013522A2/es unknown

Patent Citations (39)

Non-Patent Citations (47)

Also Published As

Similar Documents

Legal Events